

Curriculum Vitae

Name: Darrell Mealer Wilson, MD

Address: Center for Academic Medicine MC5660
Stanford University Medical Center
453 Quarry Rd, Palo Alto, CA 943045-5660

(650) 721-1811 FAX (650) 725-8375
EMail - dwilson@stanford.edu

Personal data http://med.stanford.edu/profiles/endocrinology/researcher/Darrell_Wilson/
Divisional website <http://dped.stanford.edu>

Education:

Sep 1969-Mar 1973: Bachelor of Science, Electrical Engineering, University of California, Davis, with highest honors

Mar 1973-Jun 1973: Graduate work, Electrical Engineering. University of California, Davis

Sep 1973-Jun 1977: Doctor of Medicine: concentration area, Computers in Medicine. University of California, San Diego

Postgraduate Training:

Jul 1977-Jun 1978: Intern in Pediatrics, Stanford University

Jul 1978-Jun 1980: Resident in Pediatrics, Stanford University

Jul 1980-Jun 1984: Fellow, Pediatric Endocrinology, Stanford University

Faculty Positions:

Jul 1984-Aug 1987: Clinical Assistant Professor and Physician Specialist, Stanford University Medical Center

Sep 1987-Nov 1987: Acting Assistant Professor, Stanford University

Nov 1987-Dec 1993: Assistant Professor, Stanford University

Jan 1994-Jan 2001: Associate Professor, Stanford University School of Medicine

Jan 2001-Nov 2019: Professor, Stanford University School of Medicine

Nov 2019- present: Professor Emeritus, Recalled to active duty, Stanford University School of Medicine

Mar 1998-June 2015: Chief, Division of Pediatric Endocrinology and Diabetes, Stanford University School of Medicine

Sept 2006- June 2011: Fellowship Training Program Director

June 2011 – present: Associate Fellowship Training Program Director

Clinical Positions:

Sep 1990-Aug 2000: Medical Director, Medical Information Systems, Packard Children's Hospital at Stanford

Jul 1984-May 2015: Director, Pediatric Diabetes Center, Packard Children's Hospital at Stanford

Mar 1998-Nov 2016: Service Chief, Division of Pediatric Endocrinology and Diabetes, Stanford University School of Medicine

Research Positions:

Jan 2001-Dec 2008 Site Director, Glaser Pediatric Research Network

Oct 2017-present: Member of the Stanford Diabetes Research Center

Certifications & Licenses:

Diplomate, National Board of Medical Examiners, Jul 1978

California Medical License, Nov 1978, current

Drug Enforcement Agency, current

Diplomate, American Board of Pediatrics, May 1982, #27615

Board Certified, Pediatric Endocrinology, Initial - Oct 1995, Recertified – Nov 2017, #042833

Panel Member, California Children Services #77-0465765

Stanford Radioactive Materials Use #SMN353

Bloodborne Pathogens 1 Jun 2004 #98033131

CITI and GCP - Current

Patent Applications:

2009 - Hypoglycemia Prediction Method 61/197230

US Patent Application No. 14/175,020

Title: Kalman Filter Based On-Off Switch for Insulin Pump

US Patent: 9,227,014(USA)

Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed-Loop Insulin Delivery (Stanford Docket S10-391)

Professional Societies:

The Institute of Electrical and Electronic Engineers, 1972

IEEE Engineering in Medicine and Biology Group, 1972

California Medical Association, 1974-1983

American Academy of Pediatrics, 1979-1983

American Federation of Clinical Research, 1982

American Diabetes Association, 1984

Endocrine Society, 1984

Stanford Center for Youth Development, 1984

Lawson Wilkins Pediatric Endocrine Society, 1985

Western Society for Pediatric Research, 1986

Society for Pediatric Research, 1988

International Society for Insulin-like Growth Factor Research, 1995

Medical Staff:

Darrell M Wilson

Packard Children's Hospital at Stanford, 1984-present
Stanford University Hospital, 1984-present
Dominican Hospital, Santa Cruz, 1996-2000
Santa Clara Valley Medical Center, 2006-2008

Teaching:

Director, Early Clinical Experience Program (Pediatrics 80Q),
Aug 1987 to 2006

Instructor, Endocrine Physiology Course, Stanford Medical School
1990 to present

PRECEPT Fellow Education Series, Clinical Faculty, Biostatistics,
Winter Quarter, 1996

Growth: A Measure of Health and Disease in Individuals and Societies.
Created and taught - Sophomore Seminar, Fall 1998, repeated Fall 1999

Annual Families with Diabetes Conference, Created 1999, repeated annually

PRECEPT Fellow Education Series, Co-Director, Biostatistics, in the 2000s

Introduction to Medicine, Immunology 230, Fall Quarter, 2000 and Spring of 2002, 2003, 2004,
2005, 2006, 2007, 2009-2010

Honors:

Kraft Scholarship Prize, UCD, 1969

Tau Beta Pi, 1972

Phi Kappa Phi, 1972

Engineering Council of Sacramento Valley Award, 1973

Graduated with Highest Honors, 1973

Luetje-Stubbs Faculty Scholar, 1988-89, 1989-90, 1992-1993

Honorary Board of Directors, Diabetes Society of Santa Clara Valley,
1988-1989

America's Best Doctors, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009,
2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022

Diabetes Society, San Jose, Honoree 2008

San Francisco Juvenile Diabetes Research Foundation Honoree, May 2009

2013-present – Member, CHYLD (Children with Hypoglycaemia and their Later Development)
International Advisory Group and Steering Group

Core Clerkship Honor Roll for Clinical Teaching, Stanford University, 2017

Medical Staff Distinguished Service Award, Packard, 2018

Editorial Boards:

Journal of Clinical Endocrinology and Metabolism, Jan 1989 - Dec 1992

Diabetes: Technology and Therapeutics, Jan 2000-May 2019

Journal of Diabetes Science and Technology, Jun 2006- Nov 2022

Reviewer: Multiple Journals: JAMA, Diabetes, Hormone and Metabolic Research, Hormone
Research, Journal of Clinical Endocrinology and Metabolism, Pediatrics, Sleep, Journal of
Adolescent Health Care, Journal of Endocrinological Investigation, Journal of Pediatrics,

Darrell M Wilson

Endocrinology, Diabetes Care, Pediatric Research, Growth Regulation, Addiction, Life Science, Lancet, Diabetes Technology and Therapeutics

Reviewer: Grants: Ad hoc reviewer for the National Institute on Aging, NIH; National Institute of Child Health and Human Development, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIH; March of Dimes Birth Defects Foundation, Canadian Institute of Health Research, American Biology, TMM, DIS-DIA panel: PRMRP

International and National Committees:

Diabetes Program Committee, Lawson Wilkins Pediatric Endocrine Society
Jun 1992 - Jun 1996

Local Chair, European Society of Pediatric Endocrinologist Summer
School, Jan 1993 - Jun 1993

Diabetes Prevention Trial - Type 1 Study Committees

Steering Committee - Jun 1994 – Sept 2001

Bylaws Committee - Jun 1994

Laboratory Monitoring Committee Dec 1994 – Sept 2001

Communication and Public Relations Committee, May 96-Nov 97

Co-Chair, TAP/Ross Special Conference, Puberty... When it comes too soon. Indications for treatment. Washington, DC Oct 1993

Program Committee, Lawson Wilkins Pediatric Endocrine Society, 1996
meeting

Chair, Diabetes Committee, Lawson Wilkins Pediatric Endocrine Society,
1996-1997 meeting

Medical Advisory Team, Turner's Syndrome Society of the United States,
June 1995

Chair, Electronic Communications Committee, Lawson Wilkins Pediatric
Endocrine Society, 1997 - 2001

Special Emphasis Panel Reviewer, NIH, Immunopathogenesis of Type 1
Diabetes Mellitus 1998

Ad Hoc Reviewer, Juvenile Diabetes Foundation International, Glucose Sensors, 2000

Informatics and Information Systems Committee, Association of Program Directors in
Endocrinology and Metabolism, April 2000

Data Management Taskforce, Glaser Pediatric Research Network, Jan 2000- Dec 2008

Chair, Protocol Development Taskforce, Glaser Pediatric Research Network, Jan 2000-Dec
2008

Director, Lawson Wilkins Pediatric Endocrine Society, May 2001-May 2004

Member, PES History Committee, 2013-present

NIH DirecNet Glucose Sensor Study Committees

Steering Committee - Sept 2001 – present

Outpatient protocol design committees, April 2002 – present

NIH Type 1 Diabetes TrialNet Study Committees

Steering Committee - Sept 2001 – present

Chair, Clinical Center Directors, Sept 2001-present

Natural history/screening protocol committee, March 2002-

Laboratory Monitoring Committee, March 2002-~2015

Ancillary Studies Committee, 2010-2013

Clinical Feasibility Committee, 2010-present

Metabolic Assessments Committee 2010-~2015

Clinical Monitoring Group 2015-present

Eligibility and Events 2016- present

Duality of Interest - ??- present

Major Local Committees and Courses at Stanford (full list available):

Medical Committee for the Protection of Human Subjects at Stanford

Sep 1979 - Sep 1985

Medical Committee for the Protection of Human Subjects at Stanford

(alternate member) Sep 1999-Oct 2004

Medical Committee for the Protection of Human Subjects at Stanford

Chair, Panel 5, Oct 2004-present

Pharmacy and Therapeutics Committee, Packard Children's Hospital at

Stanford, Jul 1984 - present

Clinical Laboratory Committee, Packard Children's Hospital at Stanford,

Jul 1986 - 1993

General Clinical Research Center Advisory Committee,

June 1988 – May 2008

Faculty Senate, Medical School,

Jun 1988 - Jun 1991

Ambulatory Care Committee, Packard Children's Hospital at Stanford,

May 1989

Medical Information Selection Committee, Children's Hospital at

Stanford, Jun 1989 - May 1990

Chairman, Medical Records Committee, Packard Children's

Hospital at Stanford Sept 1992 - ~1998

Starbright World Research Team, Packard Children's

1995-1997

Center for Clinical Immunology at Stanford, Stanford University Medical Center 1995-present

Continuing Medical Education Oversight Committee, Stanford University Medical Center 1996-1999

Faculty, Stanford Center on Adolescence, Stanford University 1996-present

Practice Management Group, Packard Children's Hospital 1998-present

Chair, Organization of Pediatric Endocrinologists and Annual Meeting, Sep 1999 – August 2000 and alternate years thereafter

General Clinical Research Center Safety Committee April 2001- May 2008

Stanford Children's Health Information Services Provider Advisory Group (ISPAG) 2010 to present

Community Activities:

Camp physician at the summer camp for diabetic children sponsored by the Diabetes Society of Santa Clara Valley, Jul 1980, Jul 1981, Jul 1982, Jul 1983, Aug 1992, Aug 2002, Aug 2003 and essentially annually thereafter.

Advisor, Diabetes Camp, Diabetes Society of Santa Clara Valley, Feb 1988 - 1989

Medical Director, Diabetes Summer Camp, Diabetes Society of Santa Clara Valley, 1989 - 1996

Medical Director, Diabetes Family Camp, Diabetes Society of Santa Clara Valley, Apr 1991, Apr 1992

Board of Directors, Diabetes Society of Santa Clara Valley, Nov 1989-Sep 1994

Board of Directors, American Diabetes Association, Mid-Peninsula Chapter, Feb 1996 - Jun 1997

Board of Directors, Juvenile Diabetes Research Foundation, Greater Bay Area Chapter, July 2001 - Jun 2003

Board of Directors, Juvenile Diabetes Research Foundation, Silicon Valley Chapter, July 2003 – Jun 2008

ORIGINAL PUBLICATIONS

1. **Wilson DM**, Kripke DF, McClure DK, Greenburg AG: Ultradian cardiac rhythms in surgical intensive care unit patients. *Psychosom Med* 39:432-435, 1977
<http://www.psychosomaticmedicine.org/content/39/6/432.full.pdf>
2. **Wilson DM**, Hopper AO, McDougall IR, Bayer MF, Hintz RL, Stevenson DK, Rosenfeld RG: Serum free thyroxine levels in term, premature and sick infants. *J Pediatr* 101:113-117, 1982
3. **Wilson DM**, Hintz RL: Interspecies comparison of somatomedin structure using immunological probes. *J Endocrinol* 95:59-64, 1982 PMID: 6752325
4. Rosenfeld RG, **Wilson DM**, Dollar LA, Bennett A, Hintz RL: Both human pituitary growth hormone and recombinant DNA derived human growth hormone cause insulin resistance at a post-receptor level. *J Clin Endocrinol Metab* 54:1033-1038, 1982 PMID: 7037819
5. Hintz RL, Rosenfeld RG, **Wilson DM**, Bennett A, Fenno J, McClellan B, Swift R: Biosynthetic methionyl-human growth hormone is biologically active in adult humans. *Lancet* 1:1276-1279, 1982
6. **Wilson DM**, Bennett A, Adamson GD, Nagashima RJ, Liu F, DeNatale ML, Hintz RL, Rosenfeld RG: Somatomedins in pregnancy: A cross sectional study of insulin-like growth factors I and II and somatomedin peptide content in normal human pregnancies. *J Clin Endocrinol Metab* 56:858-861, 1982
7. Luna AM, **Wilson DM**, Wibbelsman CJ, Brown R, Nagashima RJ, Hintz RL, Rosenfeld RG: Somatomedins in adolescence: A cross sectional study of the effect of puberty on plasma insulin-like growth factors I and II levels. *J Clin Endocrinol Metab* 57:268-271, 1983
8. Bennett A, **Wilson DM**, Liu F, Nagashima RJ, Rosenfeld RG, Hintz RL: Levels of insulin-like growth factors I and II in cord blood of term infants. *J Clin Endocrinol Metab* 57:608-612, 1983
9. **Wilson DM**, Enzmann DR, Hintz RL, Rosenfeld RG: Cranial computed tomography in septo-optic dysplasia: Discordance of clinical and radiologic findings. *Neuroradiology* 26:279-283, 1984
10. Bryer-Ash M, **Wilson DM**, Tune BM, Rosenfeld RG, Shochat SJ, Luetscher JA: Hypertension due to aldosterone-producing adenoma in a seven year old girl: Case report and discussion of diagnostic approach. *Am J Dis Child* 138:673-676, 1984
11. Gertner JM, Genel M, Gianfredi SP, Hintz RL, Rosenfeld RG, Tamborlane WV, **Wilson DM**: Prospective clinical trial of human growth hormone in short children without growth hormone deficiency. *J Pediatr* 104:172-176, 1984
12. Rosenfeld RG, Ceda G, **Wilson DM**, Dollar LA, Hoffman AR: Characterization of high affinity receptors for insulin-like growth factors I and II on rat anterior pituitary cells. *Endocrinology* 114:1571-1575, 1984

13. **Wilson DM**, Ceda PG, Bostwick DG, Webber RJ, Minkoff JR, Pont A, Hintz RL, Bensch KG, Kraemer FB, Rosenfeld RG, Hoffman AR: Acromegaly and Zollinger-Ellison syndrome secondary to an islet cell tumor: Characterization and quantification of plasma and tumor human growth hormone releasing factor. *J Clin Endocrinol Metab* 59:1002-1005, 1984
14. Ceda GP, Hoffman AR, Silverberg GD, **Wilson DM**, Rosenfeld RG: Regulation of growth hormone release from cultured human pituitary adenomas by somatomedins and insulin. *J Clin Endocrinol Metab* 60:1204-1209, 1985
15. Luetscher JA, Kraemer FB, **Wilson DM**, Schwartz HC, Bryer-Ash M: Increased plasma inactive renin in diabetes mellitus: A marker and possible predictor of complications. *N Engl J Med* 312:1412-1417, 1985
16. Bagdade JD, Subbaiah PV, Hintz RL, **Wilson DM**: The measurement of arterial smooth muscle cell mitogens in the blood of oral contraceptive users. *Atherosclerosis* 56:149-155, 1985
17. **Wilson DM**, Baker B, Hintz RL, Rosenfeld RG: Subcutaneous versus intramuscular growth hormone therapy: Growth and acute somatomedin response. *Pediatrics* 76:361-365, 1985
18. **Wilson DM**, Hintz RL, Ross JC, Rosenfeld RG: Sex chromosome fragment in a phenotypically normal female: Significance of Y-related material. *Clinical Pediatrics* 25:36-39, 1986
19. **Wilson DM**, Pitts WC, Hintz RL, Rosenfeld RG: Testicular tumors with Peutz-Jeghers Syndrome. *Cancer* 57:2238-2240, 1986
20. Rosenfeld RG, **Wilson DM**, Lee PDK, Hintz RL: Insulin-like growth factors I and II in growth failure: A critical evaluation. *J Pediatr* 109:428-433, 1986
21. **Wilson DM**, Hammer LD, Duncan PM, Dornbusch SM, Ritter PL, Hintz RL, Gross RT, Rosenfeld RG: Growth and intellectual development. *Pediatrics* 78:646-650, 1986
22. **Wilson DM**, Hoffman AR: Reduction of pituitary size by a somatostatin analog in a patient with an islet cell tumor secreting growth hormone releasing factor. *Acta Endocrin* 113:23-28, 1986
23. Roth KA, **Wilson DM**, Eberwine J, Dorin RI, Barchas JD, Kovacs K, Bensch KG, Hoffman AR: Acromegaly and pheochromocytoma: A multiple endocrine syndrome caused by a plurihormonal adrenal medullary tumor. *J Clin Endocrinol Metab* 63:1421-1426, 1986
24. Lee PDK, **Wilson DM**, Hintz RL, Rosenfeld RG: Growth hormone treatment of short stature in Prader-Willi syndrome. *J Pediatr Endo* 2:31-34, 1987
25. **Wilson DM**, Kraemer HC, Ritter PL, Hammer LD: Growth curves and adult height estimation for adolescents with early and late puberty. *Amer J Dis Child* 141:565-570, 1987
26. **Wilson DM**, Thomas JA, Hamm Jr TE, Wyche J, Hintz RL, Rosenfeld RG: Transplantation of insulin-like growth factor-II secreting tumors into nude rodents. *Endocrinol* 120:1896-1901, 1987

27. Bennett AE, **Wilson DM**, Rosenfeld RG, Hintz RL, Schwartz HC, Stevenson DK: Levels of insulin-like growth factors I and II in infants with idiopathic macrosomia and infants of diabetic mothers. *J Pediatr Endo* 2:23-29, 1987
28. Lee PDK, **Wilson DM**, Rountree L, Hintz RL, Rosenfeld RG: Linear growth response to exogenous growth hormone in Prader-Willi syndrome. *Am J Med Genet* 28:865-871, 1987
29. **Wilson DM**, Kei J, Hintz RL, Rosenfeld RG: Effects of testosterone enanthate therapy for pubertal delay. *Amer J Dis Child* 142:96-99, 1988
30. **Wilson DM**, Frane JW, Sherman B, Johanson AJ, Hintz RL, Rosenfeld RG: Carbohydrate and lipid metabolism in Turner syndrome: The effect of therapy with growth hormone, oxandrolone, and a combination of both. *J Pediatr* 112:210-217, 1988
31. DeLeon DD, Bakker B, **Wilson DM**, Hintz RL, Rosenfeld RG: Demonstration of insulin-like growth factor (IGF-I and -II) receptors and binding protein in human breast cancer cell lines. *Biochem Biophys Resear Comm* 152:398-405, 1988
32. Ocrant I, Valentino KL, Eng LF, Hintz RL, **Wilson DM**, Rosenfeld RG: Structural and immunohistochemical characterization of insulin-like growth factor (IGF) I and II receptors in the murine central nervous system. *Endocrinology* 123:1023-1034, 1988
33. **Wilson DM**, Stevenson DK, Luetscher JA: Plasma prorenin and renin in childhood and adolescence. *Amer J Dis Child* 124:1070-1072, 1988
34. **Wilson DM**, Baldwin RB, Ariagno RL: A randomized, placebo controlled trial of the effects of dexamethasone on the hypothalamic-pituitary-adrenal axis in preterm infants. *J Pediatr* 113:764-768, 1988
35. Lee PDK, Rountree L, Kanner A, **Wilson DM**: Reflectance meters in home blood glucose monitoring. *Practical Diabetology* 7:19-22, 1988
36. **Wilson DM**, Perkins SN, Thomas JA, Seelig S, Berry SA, Hamm Jr TA, Hoffman AR, Hintz RL, Rosenfeld RG: Effects of elevated serum insulin-like growth factor (IGF)-II on growth hormone and IGF-I mRNA and secretion. *Metabolism* 38:57-62, 1989
37. DeLeon DD, **Wilson DM**, Bakker B, Lamson G, Hintz RL, Rosenfeld RG: Characterization of insulin-like growth factor binding proteins from human breast cancer cells. *Molecular Endocrinology* 3:567-574, 1989
38. Ocrant I, Valentino KL, Hoffman AR, Hintz RL, **Wilson DM**, Rosenfeld RG: Structural characterization and immunohistochemical localization of receptors for insulin-like growth factor II in the rat pituitary gland. *Neuroendocrinology* 49:248-254, 1989
39. Luetscher JA, Kraemer FB, **Wilson DM**: Prorenin and vascular complications of diabetes. *American Journal of Hypertension* 2:382-386, 1989
40. Ocrant I, Bangs CD, Johnston KM, Donlon TA, **Wilson DM**, Hintz RL, Rosenfeld RG: Somatic and intellectual development in a patient with 47,XX,psu dic(X)(p11.2) karyotype. *Am J Med Genet* 32:536-539, 1989

41. Lee PDK, **Wilson DM**, Rountree L, Hintz RL, Rosenfeld RG: Efficacy of insulin-like growth factor I levels in predicting the response to provocative growth hormone testing. *Pediatr Research* 27:45-51, 1990
42. DeLeon DD, Bakker B, **Wilson DM**, Lamson G, Rosenfeld RG: Insulin-like growth factor binding proteins in human breast cancer cells: Relationship to hIGF-BP-2 and HIGF-BP-3). *J Clin Endocrinol Metab* 71:530-532, 1990
43. **Wilson DM**, Luetscher JA: Plasma Prorenin and complications in children with insulin-dependent diabetes mellitus. *New Engl J Med* 323:1101-6, 1990
44. Peabody CA, Warner MD, Markoff E, Hoffman A, **Wilson DM**, Csernansky JG: Growth hormone response to growth hormone releasing factor in depression and schizophrenia. *Psych Res* 33:269-276, 1990
45. Donovan SM, Hintz RL, **Wilson DM**, Rosenfeld RG: Insulin-like growth factors I and II and their binding proteins in rat milk. *Pediatr Resear* 29:50-55; 1991
46. Neely EK, Morhenn VB, Hintz RL, **Wilson DM**, Rosenfeld RG: Comparison of insulin-like growth factor receptors and binding proteins in normal and transformed human keratinocytes. *J Invest Dermatol* 96:104-110, 1991
47. Hammer LD, Kraemer HC, **Wilson DM**, Ritter PL, Dornbusch SM: Standardized percentile curves of body mass index for children and adolescents. *Amer Dis J Child* 145:259-263, 1991
48. Hammer LD, **Wilson DM**, Litt IF, Killen JD, Hayward C, Miner B, Vosti C, Taylor CB: The impact of pubertal development on body fat distribution among Caucasian, Hispanic and Asian female adolescents. *J Pediatr* 118:975-80, 1991
49. **Wilson DM**, Killen JD, Hammer LD, Litt IF, Vosti C, Miner B, Taylor CB, Hayward C: Insulin-like growth factor-I as a reflection of body composition, nutrition, and puberty in sixth and seventh grade girls. *J Clin Endocrinol Metab* 73:907-912, 1991
50. **Wilson DM**, Lee PDK, Morris AH, Reiter EO, Gertner JM, Marcus R, Quarmby VE, Rosenfeld RG: Growth hormone therapy in hypophosphatemic rickets. *Amer J Diseases Child* 145:1165-1170, 1991
51. Donovan SM, Atilano LC, Hintz RL, **Wilson DM**, Rosenfeld RG: Differential regulation of the insulin-like growth factors (IGF-I and -II) and IGF binding proteins during malnutrition in the neonatal rat. *Endocrin* 129:149-57, 1991
52. Killen JD, Hayward C, Litt I, Hammer LD, **Wilson DM**, Miner B, Vosti C, Varady A, Shisslak C: Is puberty a risk factor for eating disorders? *Amer J Dis Child* 146:323-325, 1992
53. Gregory JL, **Wilson DM**, Parker B: The overlap syndrome: An unusual presentation - Radiology Case of the Month. *Amer Dis J Child* 146:421-422, 1992
54. DeLeon DD, **Wilson DM**, Powers M, Rosenfeld RG. Effect of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. *Growth Factors* 6:327-336, 1992

55. **Wilson DM**, Stene MA, Killen JD, Hammer LD, Litt IF, Hayward C, Taylor CB. Insulin-like growth factor binding protein-3 in normal pubertal girls. *Acta Endocrinologica* 126:381-386, 1992
56. Hayward C, Killen JD, Hammer LD, Litt IF, **Wilson DM**, Simmonds B, Taylor CB: Pubertal stage and panic attack occurrence in sixth- and seventh-grade girls. *Amer J Psychiat* 149:1239-1243; 1992
57. Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, Olney R, **Wilson DM**. Two year treatment results of depot leuprolide acetate therapy for central precocious puberty. *J Pediatr* 121:634-640; 1992
58. Dawson KL, Wright AM, Bakker B, Pitlick PT, **Wilson DM**, Rosenfeld RG: Cardiovascular screening in Turner's Syndrome: Utility of MR imaging. *Australasian Radiology* 36:204-209, 1992
59. **Wilson DM**, Dotson RJN, Neely EK, Cohen P, Hintz RL, Rosenfeld RG: A randomized trial of the effects of estrogen administration on serum growth hormone concentrations following stimulation with clonidine. *Amer J Dis Child* 147:63-65, 1993
60. Robinson TN, Hammer LD, Killen JD, Kraemer HC, **Wilson DM**, Hayward C, Taylor CB: Does television viewing increase obesity and reduce physical activity? Cross-sectional and longitudinal analyses among adolescent females. *Pediatr* 91:273-280, 1993
61. Killen JD, Taylor CB, Hammer LD, Litt I, **Wilson DM**, Rich T, Hayward C, Simmonds B, Kraemer H, Varady A: Results of an attempt to modify unhealthful eating attitudes and weight regulation practice of young adolescent girls. *International J Eating Disorder* 13:369-384, 1993
62. Olney RC, Smith RL, Kee Y, **Wilson DM**. Production and hormonal regulation of insulin-like growth factor binding proteins in bovine chondrocytes. *Endocrinol* 133:563-570, 1993
63. Kuilboer MM; Shahar Y; **Wilson DM**; Musen MA. Knowledge reuse: temporal-abstraction mechanisms for the assessment of children's growth. *Proceedings Annual Symposium on Computer Applications in Medical Care*, 1993:449-53, 1993.
64. Killen JD, Hayward C, **Wilson DM**, Taylor CB, Hammer LD, Litt I, Simmonds B, Haydel F. Factors associated with eating disorder symptoms in a community sample of 6th and 7th year old girls. *Inter J Eating Disorders* 15:357-367, 1994
65. **Wilson DM**, Killen JD, Hayward C, Robinson TN, Hammer LD, Kraemer HC, Varady A, Taylor CB. Timing and rate of sexual maturation and the onset of cigarette and alcohol use among teenage girls. *Arch Pediatr Adolesc Med* 148:789-795, 1994
66. Killen JD, Taylor CB, Hayward C, **Wilson DM**, Hammer LD, Robinson TN, Litt I, Simmonds BA, Haydel F, Varady A, Kraemer. The pursuit of thinness and onset of eating disorder symptoms in a community sample of adolescent girls: A three year prospective analysis. *Inter J Eating Disorders* 16:227-238, 1994

67. Rosenfeld RG, Tesch L, et al, **Wilson DM**. Recommendations for the diagnosis, treatment and management of individuals with Turner syndrome. *The Endocrinologist* 4:351-358, 1994
68. Olney RC, Anhalt H, Neely EK, **Wilson DM**. A quantitative assay for IGF-I and IGFBP mRNAs using reverse transcription, polymerase chain reaction, and a DNA enzyme-linked immunoassay. *Molecular Cellular Endocrinol* 110:213-223; 1995
69. Neely EK, Hintz RL, **Wilson DM**, Lee PA, Gautier T, Argente J, Stene M. Normal ranges for immunochemiluminometric gonadotropin assays. *J Pediatr* 127:40-46, 1995
70. Neely EK, **Wilson DM**, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. *J Pediatr* 127:47-52, 1995
71. DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1). (**Wilson DM** is a member of the study group). Implementation of Screening and Staging of Relatives. *Transplantation Proceedings* 27:3377, 1995
72. Hayward C, Killen JD, **Wilson DM**, Hammer LD, Blair-Greiner A, Strachowski D, Taylor CB: School refusal, depression in early adolescent girls with nonclinical panic attacks. *J Anxiety Disorder* 9:329-338, 1995
73. Olney RC, **Wilson DM**, Mohtai M, Fielder PJ, Smith RL. Interleukin-1 and tumor necrosis factor-alpha increase insulin-like growth factor binding protein-3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes. *J Endocrinol* 146:279-286, 1995
74. Faust J, Rosenfeld RG, **Wilson DM**, Durham L, Vardopoulous C: Prediction of depression in the parents of Turner syndrome adolescents as a function of growth hormones, family conflict, and coping style. *Journal of Developmental and Physical Disabilities* 7:221-233, 1995
75. **Wilson DM**, McCauley E, Brown DR, Dudley R, and the Bio-Technology General Corp Cooperative Study Group. Oxandrolone therapy in constitutionally delayed growth and puberty. *Pediatr* 96:1095-1100, 1995
76. Kuilboer MM, **Wilson DM**, Musen MA, Wit JM. CALIPER: Individualized-growth curves for the monitoring of children's growth. *Medinfo* 8 Pt2:1686, 1995.
77. Killen JD, Hayward C, **Wilson DM**, Haydel F, Robinson TN, Simmonds BA, Hammer LD, Taylor CB. Predicting onset of drinking in a community sample of adolescents: The role of expectancy and temperament. *Addictive Behaviors* 21:1-8, 1996
78. Olney RC, Tsuchiya K, Mohtai M, Smith RL, Maloney WJ, Schurman DJ, **Wilson DM**. Chondrocytes from osteoarthritic cartilage have increased expression of IGF-I and IGFBP-3 and -5, but not IGF-II or IGFBP-4. *J Clin Endocrin Metab* 81:1096-1103, 1996
79. Eckert KL, **Wilson DM**, Bachrach LK, Anhalt H, Habiby RL, Olney RC, Hintz RL, Neely EK. A single sample, subcutaneous gonadotropin releasing hormone stimulation test for central precocious puberty. *Pediatrics* 97:517-19, 1996
80. Robinson TN, Killen JD, Litt IF, Hammer LD, **Wilson DM**, Haydel F, Hayward C, Taylor CB. Ethnicity and Body dissatisfaction: Are Hispanic and Asian girls at increased risk for eating disorders? *J Adol Health* 19:384-393, 1996

81. Killen JD, Taylor CB, Hayward C, Haydel F, **Wilson DM**, Hammer LD, Kraemer H, Blair-Greiner A, Strachowski. Weight concerns influence the development of eating disorder symptoms: A 4-year prospective study. *J Consult Clin Psych* 64:936-940, 1996
82. Hayward C, Killen, **Wilson DM**, Hammer LD, Litt IF, Kraemer HC, Haydel F, Varady A, Taylor CB: Psychiatric risk associated with early puberty in adolescent girls. *J Am Acad Adolesc Psychiatry* 32(2):255-262, 1997
83. Brown SJ, Lieberman DA, Gemeny BA, Fan YC, **Wilson DM**, Pasta DJ: Educational video game for juvenile diabetes: Results of a controlled trial. *Med Inform* 22:77-89, 1997
84. Killen JD, Robinson TN, Haydel F, Hayward C, **Wilson DM**, Hammer LD, Litt I, Taylor CB. Prospective study of risk factors for the onset of cigarette smoking. *J Consult Clin Psych* 65:1011-1016, 1997
85. Shahar Y, Chen H, Stites DP, Basso LV, Kaizer H, **Wilson DM**, Musen MA. Semiautomated entry of clinical temporal-abstraction knowledge. *J Am Med Inform Assoc* 6:494-511, 1999
86. Lum CK, Wang M-C, Moore E, **Wilson DM**, Marcus R, Bachrach LK. A comparison of calcaneus ultrasound and dual energy x-ray absorptiometry in healthy American youth. *J Clin Densitometry* 2:419-427, 1999.
87. Greenbaum C, Schatz D, Cuthbertson D, Zeidler A, Eisenbarth G, Krischer J, for the DPT-1 Study Group (**Wilson DM** member of Steering Committee). Islet cell antibody positive relatives with HLA DQA1*0102/DQB1*0602: Identification by the Diabetes Prevention Trial - Type 1, *J Clin Endocrin Metab*, 85:1255-1260, 2000
88. Lee PDK, Allen DB, Angulo MA, Cappa M, Carrel AL, Castro-Magana M, Chiumello G, Davies PSW, Eiholzer U, Grugni G, Haufa BP, Hintz RL, Lammer C, Mogul HR, Myers SE, Partsch CJ, Pescovitz OH, Ritzen EM, Rosenfeld RG, Sipila I, **Wilson DM**. Consensus Statement-Prader-Willi Syndrome: Growth Hormone (GH)/Insulin-Like Growth Factor Axis Deficiency and GH Treatment, *The Endocrinologist*, 10:71-73S, 2000
89. Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White N, **Wilson DM**, Wolfsdorf J, and the DPT-1 Study Group. First phase insulin release (FPIR) during the intravenous glucose tolerance test (IV-GTT) as a risk factor for Type 1 diabetes. *J Pediatrics* 138:244-249, 2001
90. Greenbaum CJ, Cuthbertson D, Krischer JP, and the Diabetes Prevention Trial of Type 1 Diabetes Study Group. Type 1 Diabetes Manifested Solely by 2-h Oral Glucose Tolerance Test Criteria. *Diabetes* 2001; 50:470-476
91. Yu L, Cuthbertson DD, Maclaren N, Jackson R, Palmer JP, Orban T, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators (**Wilson DM** member of Steering Committee). Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives Is Associated With Eligibility for the Diabetes Prevention Trial-Type 1. *Diabetes* 2001; 50: 1735-1740.

92. Wilson, DM and Buckingham, B. Prevention of Type 1a Diabetes Mellitus. *Pediatric Diabetes* 2:17-24, 2001
93. Buckingham B, Bluck B, **Wilson DM**: Intensive Diabetes Management In Pediatric Patients, *Current Diabetes Reports* 1:11-18, 2001
94. Bhatia S, Neely EK, **Wilson DM**: Pharmacokinetics of Depot-leuprolide in Children: Serum Leuprolide and Gonadotropin Concentrations Rise Rapidly after Intramuscular Injection Providing a Useful Means of Monitoring Efficacy of Therapy. *Pediatrics*, 109:E30-0, 2002
95. Cheung ATW, Price AR, Duong PL, Ramanujam S, Gut J, Larkin EC, Chen PCY, **Wilson DM**: Microvascular Abnormalities in Pediatric Diabetic Patients *Microvascular Research* 63, 252–258, 2002
96. Bhatia S, Faessen GH, Carland G, Balise RL, Gargosky SE, Druzin M, El-Sayed Y, **Wilson DM**, and Giudice L: A Longitudinal Analysis of Maternal Serum IGF-I and Total and Non-phosphorylated IGFBP-1 in Human Pregnancies Complicated by Intrauterine Growth Restriction. *JCEM* 87:1864-1870, 2002
97. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus (**Wilson DM** on Steering Committee). *New England Journal of Medicine* 346:1685-1691, 2002
98. Yu L, Cuthbertson DD, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators (**Wilson DM** on Steering Committee). Diabetes Prevention Trial 1: Prevalence of GAD and ICA512 (IA-2) Autoantibodies by Relationship to Proband. *Annals of the New York Academy of Sciences* 2002; 958:254-258.
99. Robinson TN, Killen JD, Kraemer HC, **Wilson DM**, Matheson DM, Haskell WL, Pruitt LA, Powell TM, Owens AS, Thompson NS, Flint-Moore NM, Davis GJ, Emig KA, Brown RT, Rochon J, Green S, Varady A. Dance and reducing television viewing to prevent weight gain in African-American girls: the Stanford GEMS pilot study. *Ethn Dis* 13 (suppl 1): S65-S77, 2003.
100. Daniels MW, **Wilson DM**, Paguntalan HG, Hoffman AR, Bachrach LK Bone mineral density in pediatric transplant recipients. *Transplantation*. 76:673-8, 2003
101. The Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee), The Accuracy of the CGMS™ in Children with Type 1 Diabetes: Results of the Diabetes Research in Children Network (DirecNet) Accuracy Study, *Diabetes Technology and Therapeutics* 5:781-789, 2003
102. The Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** was Chair of Writing Committee), The Accuracy of the GlucoWatch® G2™ Biographer in Children with Type 1 Diabetes: Results of the Diabetes Research in Children Network (DirecNet) Accuracy Study, *Diabetes Technology and Therapeutics* 5:791-800, 2003
103. The Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee), A Multi-center Study of the Accuracy of the One Touch Ultra Home Glucose Meter in Children with Type 1 Diabetes: Results of the Diabetes Research in Children (DirecNet) Accuracy Study, *Diabetes Technology and Therapeutics* 5:933-941, 2003

104. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS, and The Diabetes Prevention Trial–Type 1 Study Group (**Wilson DM** on Steering Committee). Screening Strategies for the Identification of Multiple Antibody Positive Relatives of Individuals with Type 1 Diabetes. *Journal of Clinical Endocrinology & Metabolism* 2003; 88:103-108.
105. Gandrud LM, Paguntalan HU, Van Wyhe MM, Kunselman BL, Leptien AD, **Wilson DM**, Eastman RC, Buckingham BA. Use of the Cygnus GlucoWatch® Biographer at Diabetes Camp, *Pediatric* 113:108-111, 2004
106. The Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee), Accuracy of the GlucoWatch G2 Biographer and the Continuous Glucose Monitoring System During Hypoglycemia Experience of the Diabetes Research in Children Network, *Diabetes Care* 27:722–726, 2004 PMID 14988292
107. Gandrud LM, **Wilson DM**. Growth Hormone Stimulation Testing in Children: Still Appropriate?, *Growth Hormone and IGF Research* 14:185-194, 2004
108. Tan CY, **Wilson DM**, Buckingham BA, Initiation of Insulin Glargine in Children and Adolescents with Type 1 Diabetes, *Pediatric Diabetes* 5:80-86, 2004
109. Teng L, Bui H, Bachrach LK, Lee P, Gagné N, Deal C, **Wilson DM**: Catch-up Growth in Severe Juvenile Hypothyroidism: Treatment with a GnRH Analog, *J Pediatric Endocrinology and Metabolism* 17:345-354, 2004
110. Badaru A, **Wilson DM**. Alternatives to growth hormone stimulation testing in children. *Trends in Endocrinology and Metabolism*. 6:252-8, 2004
111. Redondo MJ, Fain PR, Krischer JP, Yu L, Cuthbertson D, Winter WE, Eisenbarth GS; on behalf of the DPT-1 Study Group (**Wilson DM** on Steering Committee). Expression of beta-cell autoimmunity does not differ between potential dizygotic twins and siblings of patients with type 1 diabetes. *Journal of Autoimmunity* 2004; 23:275-279.
112. Krischer JP, Cuthbertson DD, Greenbaum C; Diabetes Prevention Trial-Type 1 Study Group. (**Wilson DM** on Steering Committee). Male sex increases the risk of autoimmunity but not type 1 diabetes. *Diabetes Care* 2004; 27:1985-1990.
113. Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee): Accuracy of Continuous Glucose Sensors in Healthy, Nondiabetic Children. Results of the Diabetes Research in Children Network (DirecNet) Accuracy Study. *Journal of Pediatrics* 2004; 144(6): 770-775.
114. **Wilson DM**, Wang Y, Cullen K, Baranowski T, Himes JH, Gross M, McClanahan B, Robinson T, Assessing Weight-related Biochemical Cardiovascular Risk Factors in African American Girls, *Intern J Obesity* 12 Suppl:73S-83S, 2004 PMID: 15489470
115. Himes JH, Obarzanek E, Baranowski T, **Wilson DM** , Rochon J, McClanahan BS: Early Sexual Maturation, Body Composition and Obesity in African-American Girls, *Intern J Obesity* 12 Suppl:64S-72S, 2004

116. **Wilson DM**, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A Two Center Randomized Controlled Feasibility Trial of Insulin Pump Therapy in Young Children with Diabetes, *Diabetes Care* 28:15-19, 2005 PMID 15616227
117. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes (**Wilson DM** on Steering Committee). *Diabetes Care* 28:1068-1076, 2005
118. Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW, Chase P, Fox LA, **Wilson DM**, Tsalikian E; Diabetes Research in Children Network (DirecNet) Study Group: Comparison of fingerstick Hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC Central Laboratory assay: Results of a Diabetes Research in Children Network (DirecNet) Study. *Pediatric Diabetes* 6:13-6, 2005
119. Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee), GlucoWatch® G2 Biographer (GW2B) Alarm Reliability During Hypoglycemia in Children. *Diabetes Technol Ther*, 7:440-447, 2005
120. Tansey MJ, Beck RW, Buckingham BA, Mauras N, Fiallo-Scharer R, Xing D, Killman C, Tamborlane WV, Ruedy KJ; The Diabetes Research in Children Network (DirecNet) (**Wilson DM** on Study Committee); Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. *Diabetes Technol Ther*. 2005 Feb;7(1):109-14. PMID 15738708
121. Tsalikian E, Beck RW, Kalajian A, Janz KF, Tansey MJ; Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee); Function of the GlucoWatch G2 Biographer during exercise. *Diabetes Technol Ther*. 2005 Feb;7(1):230 PMID 15738721
122. Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T, Wasserfall C, Cuthbertson D, Krischer J, DPT-1 Study Group. (**Wilson DM** is a member of the study group). High Frequency of Abnormal Glucose Tolerance in DQA1*0102/DQB1*0602 Relatives Identified as Part of the Diabetes Prevention Trial – Type 1 Diabetes. *Diabetologia* 48:68-74. 2005
123. Chase HP, Beck R, Tamborlane W, Buckingham B, Mauras N, Tsalikian E, Wysocki T, Weinzimer S, Kollman C, Ruedy K, Xing D, Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee); A randomized multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in children with type 1 diabetes. *Diabetes Care*. 2005 May;28(5):1101-6.
124. Fiallo-Scharer R; Diabetes Research in Children Network Study Group (**Wilson DM** on Study Committee); Eight-point glucose testing versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. *J Clin Endocrinol Metab*. 2005 Jun;90(6):3387-91.
125. Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee); Youth and parent satisfaction with clinical use of the GlucoWatch G2 Biographer in the management of pediatric type 1 diabetes. *Diabetes Care*. 2005 Aug;28(8):1929-35.

126. Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee); Diabetes self-management profile for flexible insulin regimens: cross-sectional and longitudinal analysis of psychometric properties in a pediatric sample. *Diabetes Care*. 2005 Aug;28(8):2034-5.
127. Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, Wysocki T, Weinzimer SA, Buckingham BA, Kollman C, Xing D, Ruedy KJ; Diabetes Research In Children Network Direcnet Study Group (**Wilson DM** on Study Committee); Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. *J Pediatr*. 2005 Oct;147(4):528-34. PMID 16227041
128. Kollman C, **Wilson DM**, Wysocki T, Tamborlane WV, Beck RW. Limitations of statistical measures of error in assessing the accuracy of continuous glucose sensors. *Diabetes Technol Ther*. 2005 Oct;7(5):665-72. PMID 16241865
129. The Diabetes Research in Children Network (Direcnet) Study Group (**Wilson DM** on Study Committee). Accuracy of Newer-Generation Home Blood Glucose Meters in a Diabetes Research in Children Network (DirecNet) Inpatient Exercise Study. *Diabetes Technol Ther*. 2005 Oct;7(5):675-680 PMID 16241867
130. **Wilson DM**, Block J. Real-time continuous glucose monitor use and patient selection: what have we learned and where are we going? *Diabetes Technol Ther*. 2005 Oct;7(5):788-91. PMID: 16241884
131. **Wilson DM**, Frane J. A brief review of the use and utility of growth hormone stimulation testing in the NCGS: do we need to do provocative GH testing? *Growth Horm IGF Res*. 2005 Jul;15 Suppl A:S21-5.
132. Rhodes, ET, Wolfsdorf, JI, Cuthbertson, DD, Feldman, HA, Ludwig, DS; Diabetes Prevention Trial-Type 1 Study Group (**Wilson DM** on Study Committee). Effect of low-dose insulin treatment on body weight and physical development in children and adolescents at risk for type 1 diabetes. *Diabetes Care* 2005; 28:1948-1953.
133. Buckingham B, Block J, Burdick J, Kalajian A, Kollman C, Choy M, **Wilson DM**, Chase P; Diabetes Research in Children Network Response to nocturnal alarms using a real-time glucose sensor. *Diabetes Technol Ther*. 2005 Jun;7(3):440-7. PMID: 15929675
134. Badaru A, **Wilson DM**, Bachrach LK, Fechner P, Gandrud LM, Durham E, Wintergerst K, Chi C, Klein KO, Kirk Neely E. Sequential Comparisons of 1-Month and 3-Month Depot Leuprolide Regimens in Central Precocious Puberty. *J Clin Endocrinol Metab*. 2006
135. The Diabetes Research in Children Network (Direcnet) Study Group (**Wilson DM** on Study Committee). The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. *Diabetes Care*. 2006 1:20-5.
136. Tsai EB, Sherry NA, Palmer JP, Herold KC, and the DPT-1 Study Group (**Wilson DM** on Study Committee). The Rise and Fall of Insulin Secretion in Type 1 Diabetes Mellitus. *Diabetologia* 2006; 49: 261-270.

137. The Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee). Psychological aspects of continuous glucose monitoring in pediatric type 1 diabetes. *Pediatr Diabetes*. 2006 Feb;7(1):32-8. PMID 16489972
138. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention Trial-1 Study Group. (**Wilson DM** on Study Committee) Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1. *Diabetes Care* 2006; 29: 643-649
139. Diabetes Research in Children Network (DirecNet) Study Group, Tsalikian E, Kollman C, Tamborlane WB, Beck RW, Fiallo-Scharer R, Fox L, Janz KF, Ruedy KJ, **Wilson D**, Xing D, Weinzimer SA Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. *Diabetes Care*. 2006 29:2200 PMID 17003293
140. Chi CH, Wang Y, **Wilson DM**, Robinson TN. Definition Of Metabolic Syndrome In Preadolescent Girls *J Pediatr* 148:788-92, 2006 PMID: 16769388
141. Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kache S, **Wilson DM**. Association of Hypoglycemia, Hyperglycemia, and Glucose Variability With Morbidity and Death in the Pediatric Intensive Care Unit. *Pediatrics* 118:173-9, 2006 PMID 16818563
142. Diabetes Research In Children Network (Direcnet) Study Group. (**Wilson DM** on Writing Committee). Evaluation of Factors Affecting CGMS Calibration. *Diabetes Technol Ther*. 8:318-25, 2006 PMID: 16800753
143. **Wilson, DM**. Impact of Real-Time Continuous Glucose Monitoring on Children and Their Families; *Journal Diabetes Science and Technology*, 1:146 – 150, 2006
144. Fox L, Dontchev M, Ruedy K, Beck R, Kollman C, Messer L, Coffey J, **Wilson DM**, Doyle E, Tamborlane W, Steffes M. Relative Inaccuracy of the A1cNow in Children With Type 1 Diabetes. *Diabetes Care* 30:135-7, 2007 PMID: 17192346
145. **Wilson DM**, Beck RW, Tamborlane WV, Dontchev MJ, Kollman C, Chase P, Fox LA, Ruedy KJ, Tsalikian E, Weinzimer SA. The Accuracy of the FreeStyle Navigator Continuous Glucose Monitoring System in Children With Type 1 Diabetes. *Diabetes Care*. 30:59-64, 2007 PMID: 17192334
146. Barker JM, McFann K, Harrison LC, Furlanos S, Krischer JP, Cuthbertson D, Chase HP, Eisenbarth GS, and the DPT-1 Study Group (**Wilson DM** on Study Group).. Pre-Type 1 Diabetes Dysmetabolism: Maximal sensitivity achieved with both Oral and Intravenous Glucose Tolerance Testing. *Journal of Pediatrics* 2007; 150:31-36
147. Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Group). Relative Accuracy of the BD Logic® and FreeStyle® Blood Glucose Meters. *Diabetes Technol Ther* 9:165-8, 2007
148. Robinson TN, Kraemer HC, Matheson DM, Obarzanek E, **Wilson DM**, Haskell WL, Pruitt LA, Thompson NS, Haydel FK, Fujimoto M, Varady A, McCarthy S, Watanabe C, Killen JD. Stanford GEMS phase 2 obesity prevention trial for low-income African-American girls:

Design and sample baseline characteristics, *Contemp Clin Trials* 2008 Jan;29(1):56-69
PMID: 17600772 PMID: PMC225927

149. Diabetes Research in Children Network (DirecNet) Study Group. (**Wilson DM** on Study Committee) Impaired overnight counterregulatory hormone responses to spontaneous hypoglycemia in children with type 1 diabetes. *Pediatr Diabetes*. 2007 8:199-205.
150. Gandrud LM, Xing D, Kollman C, Block JM, Kunselman B, **Wilson DM**, Buckingham BA. The Medtronic MiniMed Gold Continuous Glucose Monitoring System: An Effective Means to Discover Hypo- and Hyperglycemia in Children Under 7 Years of Age. *Diabetes Technol Ther*. 2007 9:307-16. PMID 17705686
151. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention Trial-1 Study Group (**Wilson DM** on Study Group).. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial- Type 1. *Diabetes Care* 2007; 30:38-42.
152. Barker JM, McFann KK, Orban T, on behalf of the DPT-1 Study Group (**Wilson DM** on Study Group). Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. *Diabetologia* 2007; 50:1603-1606.
153. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, and Diabetes Prevention Trial-Type 1 Study Group (**Wilson DM** on Study Group).The Role of Insulin Resistance in Predicting the Progression to Type 1 Diabetes. *Diabetes Care* 2007; 30:2314–2320.
154. Johnson, SB, Baughcum, AE, Hood K, Rafkin-Mervis, LE, Schatz, DA, for the DPT-1 Study Group (**Wilson DM** on Study Group). Participant and Parent Experiences in the Parenteral Insulin Arm of the Diabetes Prevention Trial for Type 1 Diabetes. *Diabetes Care*, 2007; 30:2193–2198.
155. Wintergerst KA, Deiss D, Buckingham B, Cantwell M, Kache S, Agarwal S, **Wilson DM**, Steil G. Glucose control in pediatric intensive care unit patients using an insulin-glucose algorithm. *Diabetes Technol Ther*. 2007 Jun;9(3):211-22. PMID: 17561791
156. Research in Children Network (DirecNet) Study Group, Buckingham B, Beck RW, Tamborlane WV, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy KJ, Tansey M, Weinzimer SA, Wysocki T. (**Wilson DM** on Study Committee) Continuous glucose monitoring in children with type 1 diabetes. *J Pediatr*. 2007 Oct;151(4):388-93, 393.e1-2. Epub 2007 Aug 24. PMID: 17889075
157. The Diabetes Research in Children Network (DirecNet) Study Group. (**Wilson DM** Chair of the Writing Committee). The relationship of A1c to glucose concentrations in children with type 1 diabetes: Assessments by high frequency glucose determinations by sensors. *Diabetes Care*. 2008 Mar;31(3):381-5. Epub 2007 Dec 4 PMID: 18056888
158. The Diabetes Research in Children Network (DirecNet) Ruedy KJ, Beck RW, Xing D, Kollman C. (**Wilson DM** on Study Committee) Availability of Protocol Datasets. *J Diabetes Sci Technol*. 5:738-745. 2007

159. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS; the Diabetes Prevention Trial-1 Study Group (**Wilson DM** on Steering Committee), A Risk Score for Type 1 Diabetes Derived from Autoantibody Positive Participants in The Diabetes Prevention Trial- Type 1, *Diabetes Care* 30:528-33 2008
160. Research in Children Network (DirecNet) Study Group, (**Wilson DM** on Study Committee) FreeStyle Navigator Continuous Glucose Monitoring System Use in Children with Type 1 Diabetes using glargine-based multiple daily dose regimens: Results of a Pilot Trial. *Diabetes Care* 31:525-7 2008 PMID 18096811
161. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, and the Type 1 Diabetes TrialNet Study Group (**Wilson DM** on Steering Committee). Type 1 Diabetes TrialNet – An International Collaborative Clinical Trials Network. *Annals of the New York Academy of Sciences* 1150:14-24, 2008
162. Skyler JS and the Type 1 Diabetes TrialNet Study Group (**Wilson DM** on Steering Committee). Update on Worldwide Efforts to Prevent Type 1 Diabetes. *Annals of the New York Academy of Sciences* 1150, 190-196, 2008
163. Diabetes Research In Children Network (DirecNet) Study Group. (**Wilson DM** on Study Committee) Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator). *Pediatr Diabetes*.9:142-7, 2008 PMID 18221427
164. Diabetes Research in Children Network (DirecNet) Study Group. (**Wilson DM** on Study Committee) Adiponectin and catecholamine concentrations during acute exercise in children with type 1 diabetes *Pediatr Diabetes*. 9:221-7, 2008 PMID 18547236
165. JDRF CGM Study Group (**Wilson DM** on Study Committee), JDRF Randomized Clinical Trial to Assess the Efficacy of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes: Research Design and Methods, *Diabetes Technology & Therapeutics*, 10:310-321, 2008.
166. The Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee), The Accuracy of the Guardian RT Continuous Glucose Monitor in Children with Type 1 Diabetes, *Diabetes Technology & Therapeutics*,10:266-272, 2008. PMID: 18828242
167. **Wilson D**, Chase HP, Kollam C, Xing D, Caswell K, Tansey M, Fox L, Weinzimer S, Beck R, Ruedy K, Tamborlane W; the Diabetes Research in Children Network (DirecNet) Study Group. Low-fat vs. high-fat bedtime snacks in children and adolescents with type 1 diabetes. *Pediatric Diabetes* 9 (Part I):320–325, 2008. PMID: 15929675
168. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Continuous (**Wilson DM** on Study Committee), Glucose Monitoring and Intensive Treatment of Type 1 Diabetes, *New England Journal of Medicine* 359:1464-1476, 2008 PMID: 18779236
169. Buckingham B, Lecher T, Hanas R, Kaiserman K, Cameron F, **Wilson, DM**. Duration of Nocturnal Hypoglycemia Prior to Seizures. *Diabetes Care* 31:2110–2112, 2008 PMID: 18694975.

170. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group (**Wilson DM** is a member of the study group). Glucose and C-peptide Changes in the Peri-Onset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. *Diabetes Care* 2008; 31: Jul 23. [Epub ahead of print].
171. Butty V, Campbell C, Mathis D, Benoist C, and the Diabetes Prevention Trial-Type 1 Study Group (**Wilson DM** is a member of the study group). Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the DPT1 trial. *Diabetes* 2008; 57: 2348-2359.
172. Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group. (**Wilson DM** is a member of the study group) Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes. *Pediatric Diabetes* 2008; [Epub ahead of print] doi: 10.1111/j.1399-5448.2008.00463.x.
173. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H and The Type 1 Diabetes TrialNet Research Group (**Wilson DM** on Study Committee) and The European C-peptide Trial Study Group The Mixed Meal Tolerance Test Versus The Glucagon Stimulation Test For The Assessment Of Beta-Cell Function In Therapeutic Trials In Type 1 Diabetes, *Diabetes Care* 31:1966 2008 PMID 18628574
174. Glaser NS, Styne DM; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group (**Wilson DM** on Study Group). Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. *Pediatrics*. 2008 Mar;121 (3):e481-8. Epub 2008
175. Klonoff DC, Bergenstal R, Blonde L, Boren SA, Church TS, Gaffaney J, Jovanovic L, Kendall DM, Kollman C, Kovatchev BP, Leippert C, Owens DR, Polonsky WH, Reach G, Renard E, Riddell MC, Rubin RR, Schnell O, Siminiere LM, Vigersky RA, **Wilson DM**, Wollitzer AO. Consensus report of the coalition for clinical research-self-monitoring of blood glucose. *J Diabetes Sci Technol*. 2008 Nov;2(6):1030-53 PMID:19885292 PMCID: PMC2769823
176. The Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** on Study Committee), Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy, *Pediatric Diabetes* 10:91–96, 2009 PMID 19175899
177. Triolo TM, Chase HP, Barker JM, for the DPT-1 Study Group (**Wilson DM** is a member of the study group). Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. *Diabetes Care* 2009; 32:769-773.
178. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Skyler JS, and the DPT-1 Study Group Group (**Wilson DM** on Study Committee). Incident Dysglycemia and the Progression to Type 1 Diabetes among Participants in the Diabetes Prevention Trial-Type 1. *Diabetes Care* 2009; 32: 1603-1607

- 179.** Pescovitz MD, Greenbaum CJ, Krause-Steinrauf , Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, **Wilson DM**, Lachin JM, Skyler JS, for the Type 1 Diabetes TrialNet Anti-CD20 Study Group, Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function, *New Engl J Med* 361:2143-2152, 2009 PMID 19940299
- 180.** Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz DA, Eisenbarth GS, and the DPT-1 Study Group (**Wilson DM** is a member of the study group). Pancreatic Islet Cell Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). *Diabetes Care* 2009; 32:2269-2274.
- 181.** Diabetes Research in Children Network (DirecNet) Study Group Blunted Counter-regulatory Hormone Responses to Hypoglycemia in Young (**Wilson DM** on the Study Committee), Children and Adolescents with Well-controlled Type 1 Diabetes, *Diabetes Care* 32:1954–1959, 2009 PMID: 19675205
- 182.** Mahon J, Sosenko JM, Rafkin-Mervis LE, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group (**Wilson DM** on the Study Group). The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. *Pediatric Diabetes* 2009: 10:97-104.
- 183.** Herold KC, Brooks-Worrell B, Palmer JP, Dosch HM, Peakman M, Gottlieb PA, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM, and The Type 1 Diabetes TrialNet Research Group (**Wilson DM** on Study Group). . Validity and Reproducibility of Measurement of Islet Autoreactivity by T-cell Assays in Subjects with Early Type 1 Diabetes. *Diabetes* 2009; 58:2588-2595.
- 184.** Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group. (**Wilson DM** on the Study Group). Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes. *Pediatric Diabetes* 2009; 10:177-183.
- 185.** Lenders CM, Feldman HA, Von Scheven E, Merewood A, Sweeney C, **Wilson DM**, Lee PDK, Abrams SH, Gitelman S, Wertz M, Klish WJ, Taylo Gr, Chen T, Holick MF for The Elisabeth Glaser Pediatric Research Network Obesity Study Group. Relation of body fat indices to vitamin D status and deficiency among obese adolescents. *Am J Clin Nutr.* 2009 Sep;90(3):459-67. PMID: 19640956
- 186.** The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (**Wilson DM** on Study Committee), Factors predictive of use and of benefit from continuous glucose monitoring in Type 1 Diabetes. *Diabetes Care* 2009;32:1947-1953
- 187.** The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (**Wilson DM** is a member of the Study Group), Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes. *Diabetes Care* 32:2047-2049, 2009 PMID: 19675193
- 188.** Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler, JS, for the DPT-1 Study Group. (**Wilson DM** is a member of the Study Group) Progression to diabetes in relatives of patients

with type 1 diabetes: mechanisms and mode of onset. *Diabetes*; 2009, Dec 22. [Epub ahead of print]

189. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum CJ, Eisenbarth GS, Skyler JS, and the DPT-1 Study Group (**Wilson DM** is a member of the Study Group). Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges with Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. *Diabetes Care*; 2009, Dec 23. [Epub ahead of print]
190. Messer L, Ruedy K, Xing D, Coffey J, Englert K, Caswell K and Ives B for the Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** is a member of the Study Group). Educating Families on Real Time Continuous Glucose Monitoring: The DirecNet Navigator Pilot Study Experience. *Diabetes Educ.* 2009 Jan-Feb; 35(1): 124-35
191. Glaser Pediatric Research Network Obesity Study Group (**Wilson DM** Chair of the Writing Committee). Intraperitoneal Fat and Insulin Resistance in Obese Adolescents. *Obesity* 18:402-409, 2010 PMID: 19713950
192. Glaser Pediatric Research Network Obesity Study Group (**Wilson DM** Chair of the Writing Committee). Metformin XR Treatment of Adolescent Obesity: A 48-Week Randomized, Double Blind, Placebo Controlled Trial with 48 Week Follow Up. *Archives of Pediatrics & Adolescent Medicine* 164:116-123, 2010
193. Fuld K, Conrad B, Buckingham BA, **Wilson DM**. Insulin Pump Use and Its Efficacy in Preschool Aged Children. *Diabetes Technology & Therapeutics* June 2010, 12(S1): S-67-S-71
194. Dassau E, Cameron F, Lee H, Bequette BW, Zisser H, Jovanovič L, Chase HP, **Wilson DM**, Buckingham BA, Doyle III FJ. Real-time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring (CGM), A Safety Net for the Artificial Pancreas, *Diabetes Care* 33:1249-1254, 2010 PMID: 20508231
195. Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (**Wilson DM** is a member of the study group). The cost-effectiveness of continuous glucose monitoring in type 1 diabetes..*Diabetes Care.* 2010 Jun;33(6):1269-74. PMID: 20332354
196. The Juvenile Diabetes Research Foundation CGM Study Group, (**Wilson DM** on the Writing Committee) Variation of Interstitial Glucose Measurements Assessed by Continuous Glucose Monitors in Healthy, Non-diabetic Individuals. *Care.* 2010 Jun;33(6):1297-9. PMID: 20215454
197. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Continuous (**Wilson DM** on Study Committee), Effectiveness of Continuous Glucose Monitoring in a Clinical Care Environment: Evidence from the JDRF-CGM Trial, *Diabetes Care* 2010;33:17-22. PMID 19837791
198. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (**Wilson DM** is a member of the Study Group) Validation of Measures of Satisfaction With

and Impact of Continuous and Conventional Glucose Monitoring Diabetes, Diabetes Technology & Therapeutics 12:679-684, 2010

199. Miller BS, Shulman D, Shillington A, Harshaw Q, **Wilson DM**, Schwartz D, Kappy M, Bakker B and Wyatt DT. Consensus and Discordance in the Management of Growth Hormone–Treated Patients: Results of a Knowledge, Attitudes, Beliefs, and Practices (KABP) Survey. International Journal of Pediatric Endocrinology vol 2010., Article ID 891571, 10 pages doi:10.1155/2010/891571, 2010
200. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, **Wilson DM**, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS for the Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to Preserve beta-cell function with Mycophenolate Mofetil and Daclizumab Combined Therapy in patients with new onset Type 1 Diabetes. Diabetes Care 2010 Apr;33(4):826-32. 2010 PMID 20067954
201. Sosenko JM, Mahon J, Rafkin L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS; Diabetes Prevention Trial-Type 1 and TrialNet Study Groups (**Wilson DM** is a member of both study groups) . A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatr Diabetes. 2010 May 26. [Epub ahead of print]
202. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, (**Wilson DM** on the Writing Committee) Prolonged Nocturnal Hypoglycemia is Common During 12 Months of Continuous Glucose Monitoring in Children and Adults with Type 1 Diabetes. Diabetes Care 33:1004-1008, 2010
203. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (**Wilson DM** is a member of the study group) Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow up of the JDRF Continuous Glucose Monitoring Randomized Trial. Diabetes Technol Ther 2010; 12: 507-515.
204. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. (**Wilson DM** is a member of the study group) Does Continuous Glucose Monitoring Affect Quality of Life for Children and Adults with Type 1 Diabetes? Findings from the JDRF Continuous Glucose Monitoring Randomized Trial. Diabetes Care 2010; 33:2175-2177.
205. Robinson TN, Matheson DM, Kraemer HC, **Wilson DM**, Obarzanek, E, Thompson NS, Alhassan,S, Spencer, TR, Haydel KF, Fujimoto M, Varady A, Killen JD. A Randomized controlled trial of culturally-tailored dance and reducing screen time to prevent weight gain in low-income African-American girls: Stanford GEMS. Arch Pediatr Adolesc Med. 2010;164(11):995-1004 PMID: 21041592 PMCID: PMC3763243
206. Forghani N, Lum C, Krishnan S, Wang,J, **Wilson DM**, Blackett PR, Malloy PJ, Feldman D. Two new unrelated cases of hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from the same novel nonsense mutation in the vitamin D receptor gene, Journal of Pediatric Endocrinology & Metabolism, 23, 843-850 (2010)
207. Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC) Hilner JE, Perdue LH, Sides EG,

- Pierce JJ, Wagner AM, Aldrich A, Loth A, Albret L, Wagenknecht LE, Nierras C, Akolkar B; T1DGC Collaborators (425))Clin Trials. 2010;7(1 Suppl):S5-S32.
- 208.** Vehik K, Haller MJ, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer J, the DPT 1 Study Group (**Wilson DM** is a member of both study groups). Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for Repeat Screening Throughout Childhood. *Diabetes Care*, 2011 34(2):358-62. PMID:21270193
- 209.** Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. (**Wilson DM is Chair** of the Writing Committee) A1c and Mean Glucose: Analysis of Data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial, *Diabetes Care* 34(3):540-42011 PMC3041177
- 210.** Cameron F, Bequette BW, **Wilson DM**, Buckingham BA, Lee H, Niemeyer G, A Closed-Loop Artificial Pancreas Based on Risk Management. *J Diabetes Sci Technol* 2011;5(2):368-379 PMID:21527108
- 211.** Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. (**Wilson DM** is Chair of the Writing Committee). Persistence of Individual Variations in Glycated Hemoglobin: Analysis of Data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial, *Diabetes Care* Jun;34(6):1315-7 2011. Epub 2011 Apr 19. PMID:21505208
- 212.** Aye T, Park Y, Reiss AL, Schleifer K, Kesler S, Baumgartner H, Hoang S, **Wilson DM**, Drobny J, Buckingham BA. The Feasibility of Detecting Neuropsychologic and Neuroanatomic Effects of Type 1 Diabetes in Young Children. *Diabetes Care*. 2011 Jul;34(7):1458-62. Epub 2011 May 11 PMID:21562318
- 213.** Xing D, Kollman C, Beck RW, Tamborlane WV, Laffel L, Buckingham BA, **Wilson DM**, Weinzimer S, Fiallo-Scharer R, Ruedy KJ for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Optimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring. *Diabetes Technology & Therapeutics*13:351-8,2011 PMID:21299401
- 214.** Vehik K, Cuthbertson D, Ruhlrig H, Schatz DA, Peakman M, Krischer JP For The DPT-1 And TrialNet Study Group (**Wilson DM** is a member of both study groups). Long-Term Outcome of Individuals Treated With Oral Insulin, *Diabetes Care* Publish Ahead of Print, published online May 24, 2011 Jul;34(7):1585-90 2011 PMID:21610124
- 215.** Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; the TrialNet and Diabetes Prevention Trial–Type 1 Study Groups (**Wilson DM** is a member of both study groups). Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. *Diabetes Care*, June 16, 2011. PMID: 21680724.
- 216.** Beck R, Steffes M, Xing D, Ruedy K, Mauras N, **Wilson DM**, Kollman C, and the Diabetes Research in Children Network (DirecNet) Study Group, The Interrelationships of Glycemic Control Measures: HbA1c, Glycated Albumin, Fructosamine, 1,5-Anhydroglucitol, and Continuous Glucose Monitoring *Pediatr Diabetes*. 2011 Apr 172011 Dec;12(8):690-5.. Epub 2011 Apr 17. PMID:21496193

- 217.** Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, **Wilson DM**, Krischer JP, Skyler JS, and the Type 1 Diabetes TrialNet GAD Study Group*. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. *Lancet*, Epub June 27, 2011. 2011 Jul 23;378(9788):319-27.PMID:21714999
- 218.** Orban T, Bundy B, Becker DJ, DiMeglio L, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran AM, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, **Wilson DM**, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: A Randomized Double-Masked Controlled Trial. *Lancet* Jul 30;378(9789):412-9. Epub 2011 Jun 28. PMID:21719096
- 219.** Herold K, Pescovitz M, McGee P, Krause-Steinrauf H, Spain L, Bourcier K, Asare A, Liu Z, Lachin J, Dosch HM, for the Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the study group) . Increased T Cellular Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20 Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes. *J Immunology, J Immunol.* 2011 Aug 15;187(4):1998-2005. Epub 2011 Jul 20. PMID:21775681
- 220.** Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP for the TrialNet Natural History Study Group (**Wilson DM** is a member of the study group). Development of Autoantibodies in the TrialNet Natural History Study (NHS). *Diabetes Care*, accepted May 30, 2011, [Epub July 12, 2011] 2011 Sep;34(9):1897-901. Epub 2011 Jul 12. PMID:21750277
- 221.** Tansey M, Laffel L, Cheng J, Beck R, Coffey J, Huang E, Kollman C, Lawrence J, Lee J, Ruedy K, Tamborlane W, Wysocki T, Xing D on behalf of Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (**Wilson DM** is a member of the study group). Satisfaction with continuous glucose monitoring in adults and youths with Type 1 diabetes. *Diabet. Med.* 28, 1118–1122, 2011 PMID:21692844
- 222.** Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G, Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Study Groups (**Wilson DM** is a member of both study groups). A Longitudinal Study of GAD65 and ICA512 Autoantibodies during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) Participants. *Diabetes Care.* 2011 Nov;34(11):2435-7.Epub 2011 Sep 12. PMID:21911777
- 223.** Mahon JL, Beam CA, Marcovina SM, Boulware DC, Palmer UP, Winter William E, Skyler JS, Krischer JP and the Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the study group). Comparison of Two Insulin Assays for First-Phase Insulin Release in Type 1 Diabetes Prediction and Prevention Studies. *Clinica Chimica Acta*, [Epub Aug 6, 2011] 2011 Nov 20;412(23-24):2128-31. Epub 2011 Aug 6. PMID 21843518
- 224.** Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C Herold KC, Skyler JS, Weinberg A and the Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the study group). Effect of Rituximab on Human In Vivo Antibody Immune Responses. *J Allergy Clin Immunol* Dec;128(6):1295-1302.e5, 2011 Sept 9 Epub PMID:21908031

- 225.** Lachin JM, McGee PL, Greenbaum CJ, Palmer J, Pescovitz MD, Gottlieb P, Skyler J for the Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the study group) . Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Diabetes. PLOS One, 2011;6(11):e26471. Epub 2011 Nov 10. PMID:22102862
- 226.** Mauras, N Beck R, Xing D, Ruedy K, Buckingham B, Tansey M, White NH, Weinzimer SA, Tamborlane W, Kollman C and the Diabetes Research In Children Network (DirecNet) Study Group (**Wilson DM** is a member of the study group) . A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years Diabetes Care December 30, 2011 2012 Feb;35(2):204-10. Epub 2011 Dec 30. PMID:22210571
- 227.** Hunt KA, Smyth DJ, Balschun T, Ban M, Mistry V, Ahmad T, Anand V, Barrett JC, Bhaw-Rosun L, Bockett NA, Brand OJ, Brouwer E, Concannon P, Cooper JD, Dias KR, van Diemen CC, Dubois PC, Edkins S, Fölster-Holst R, Fransen K, Glass DN, Heap GA, Hofmann S, Huizinga TW, Hunt S, Langford C, Lee J, Mansfield J, Marrosu MG, Mathew CG, Mein CA, Müller-Quernheim J, Nutland S, Onengut-Gumuscu S, Ouweland W, Pearce K, Prescott NJ, Posthumus MD, Potter S, Rosati G, Sambrook J, Satsangi J, Schreiber S, Shtir C, Simmonds MJ, Sudman M, Thompson SD, Toes R, Trynka G, Vyse TJ, Walker NM, Weidinger S, Zhernakova A, Zoledziewska M; Type 1 Diabetes Genetics Consortium (**Wilson DM** is a member of this Consortium); UK Inflammatory Bowel Disease (IBD) Genetics Consortium; Wellcome Trust Case Control Consortium, Weersma RK, Gough SC, Sawcer S, Wijmenga C, Parkes M, Cucca F, Franke A, Deloukas P, Rich SS, Todd JA, van Heel DA. Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry Nat Genet. 2011 Dec 27;44(1):3-5. doi: 10.1038/ng.1037.
- 228.** Yu L, Herold K, Lachin J, Bundy B, Pugliese A, Krischer J, Eisenbarth G, Pescovitz M, Type 1 Diabetes TrialNet Anti-CD20 Study Group (**Wilson DM** is a member of the study group) . Rituximab Selectively Suppresses Specific Islet Antibodies. Diabetes, 2012 35(6):1213-8. PMID:22446173.
- 229.** Tsalikian E, Fox L, Weinzimer S, Buckingham B, White NH, Beck R, Kollman C, Xing D, Ruedy K and the Diabetes Research in Children (**Wilson DM** is a member of the study group) Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatric Diabetes 2012 Jun;13(4):301-7. PMID:22151826
- 230.** Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K, On Behalf Of The Diabetes Research In Children Network (DirecNet) Study Group* (**Wilson DM** is a member of the study group) Achievement of Target A1c Levels with Negligible Hypoglycemia and Low Glucose Variability in Youth with Short-Term Type 1 Diabetes and Residual beta-cell function. Diabetes Care 2012 2012 Apr;35(4):817-20. Epub 2012 Feb 8. PMID:22323414
- 231.** Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; for the Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the study group) Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. Diabetes Care. 2012 Diabetes Care. 2012 Jun;35 (6):1213-8. Epub 2012 Mar 23. PMID:22446173

- 232.** Ruedy KJ, Tamborlane WV, for the Juvenile Diabetes Research Foundation The Landmark JDRF Continuous Glucose Monitoring Study Group (**Wilson DM** is a member of the study group). The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence. *J of Cardiovasc Trans Res* Aug;5(4):380-7. Epub 2012 Apr 27. PMID:22538483
- 233.** Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, The Type 1 Diabetes TrialNet And Diabetes Prevention Trial–Type 1 Study Groups (**Wilson DM** is a member of the study group). The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes. *Diabetes Care*. 2012 Jul;35(7):1552-5 Epub 2012 Apr 30. PMID:22547092
- 234.** Aye T, Barnea-Goraly N, Ambler C, Hoang S, Schleifer K, Park Y, Drobny J, **Wilson DM**, Reiss AL, Buckingham BA. White Matter Structural Differences in Young Children with Type 1 Diabetes: A Diffusion Tensor Imaging Study *Diabetes Care* Nov;35(11):2167-73. Epub 2012 Sep 10. PMID:22966090
- 235.** Tsalikian E, Fox L, Weinzimer S, Buckingham B, White NH, Beck R, Kollman C, Xing D, Ruedy K; Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** is a member of the study group). Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. *Pediatr Diabetes*. 2012 Jun;13(4):294-300 PMID: 22151826.
- 236.** Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the study group). Fall in C-peptide Over First Two Years from Diagnosis: Evidence of At Least Two Distinct Phases from Composite TrialNet Data. *Diabetes* 2012; June 11 Epub Ahead of Print. PMID 22688329
- 237.** Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Rewers M, Schatz DA, Krischer JP, and the TEDDY, TRIGR, Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Natural History Study Groups (**Wilson DM** is a member of the study group). Performance of Glycated Hemoglobin (HbA1c) as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. *Diabetes Care* 2012; June 14 Epub Ahead of Print. PMID 22699293
- 238.** Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP and the DPT-1 Study Group. (**Wilson DM** is a member of the study group). Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High Risk Population - Receiver Operating Characteristic Analysis. *Diabetes Care* 35:1975, 2012; Jul 11 PMID 22787174
- 239.** Cameron F, **Wilson DM**, Buckingham BA, Arzumanyan H, Clinton P, Chase HP, Lum J, Maahs DM, Calhoun PM, Bequette BW. Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm *J Diabetes Sci Technol* 2012;6(5):1142-1147 PMID:23063041
- 240.** Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A; for the Type I Diabetes TrialNet Daclizumab/Mycophenolic Acid Study Group (**Wilson DM** is member of the study group) Epstein Barr and other Herpes Virus Infections in Early Onset Type I Diabetics Treated with Daclizumab and Mycophenolate Mofetil. *Clin Infect Dis*. 2012 Oct 5. [Epub ahead of print] PMID:23042974

- 241.** Ruedy KJ, Tamborlane WV; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (**Wilson DM** is member of the study group). The landmark JDRF continuous glucose monitoring randomized trials: a look back at the accumulated evidence. *J Cardiovasc Transl Res.* 2012 Aug;5:380-7. Epub 2012 Apr 27 PMID:22538483
- 242.** Kroll JL, Beam C, Li S, Viscidi R, Pescovitz M, Weinberg A, the Type 1 Diabetes TrialNet Anti CD-20 Study Group (**Wilson DM** is member of the study group). Reactivation of Latent Viruses in Individuals Receiving Rituximab for New Onset Type 1 Diabetes. *J Clin Virol* February 17, 2013 Epub ahead of print. PMID 23422292.
- 243.** Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A for the Type 1 Diabetes TrialNet Daclizumab/Mycophenolic Acid Study Group (**Wilson DM** is member of the study group). Epstein Barr & Other Herpesvirus Infections in Patients with Early Onset Type 1 Diabetics Treated with Daclizumab & Mycophenolic Mofetil. *Clinical Infectious Diseases* 2013; 56:248-254. PMID 23042974
- 244.** Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, **Wilson DM**, Krischer JP, Skyler JS, for the Type 1 Diabetes TrialNet Canakinumab Study Group*, and Pickersgill L, de Koning E, Ziegler A, Böehm B, Badenhop B, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T for the AIDA Study Group*, *Lancet Lancet.* 2013 Jun 1;381(9881):1905-15 PMID: 23562090
- 245.** Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups* (**Wilson DM** is a member of both study groups). The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes Diagnosis *Diabetes Technology & Therapeutics* 15:401-408, 2013 PMID:23570538
- 246.** Tansey M, Weinzimer S, Beck R, Ruedy K, Cheng P, Tamborlane W, Kollman C, Mauras N, Fox L, Coffey J, White NH; Diabetes Research in Children Network (DirecNet) Study Group (**Wilson DM** is a member of the study group). Extended 6-month follow-up of a randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. *Diabetes Care* 36:e63, 2013 PMID:23613604
- 247.** Sherr J, Xing D, Ruedy KJ, Beck RW, Kollman C, Buckingham B, White NH, Fox L, Tsalikian E, Weinzimer S, Arbelaez AM, Tamborlane WV; for the Diabetes in Children Network (DirecNet) (**Wilson DM** is a member of the study group). Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes. *Diabetes Care.* 2013 Apr 22. [Epub ahead of print]
- 248.** Lenders CM, Lee PD, Feldman HA, **Wilson DM**, Abrams SH, Gitelman SE, Klish WJ, Wertz MS, Taylor GA, Alongi RT, Chen TC, Holick MF. A cross-sectional study of osteocalcin and body fat measures among obese adolescents. *Obesity (Silver Spring).* 2013; 21 (4): 808-11 PMID: 23712984
- 249.** Buckingham BA, Cameron F, Calhoun P, Maahs DM, **Wilson DM**, Chase HP, Bequette BW, Lum J, Sibayan J, Beck RW, Kollman C. Outpatient Safety Assessment of an In-Home Predictive Low-Glucose Suspend System with Type 1 Diabetes Subjects at Elevated Risk of Nocturnal Hypoglycemia *Diabetes Technology & Therapeutics* 15:8 622-627, 2013, PMID: 23883408

- 250.** Arbelaez AM, Xing D, Cryer PE, Kollman C, Beck RW, Sherr J, Ruedy KJ, Tamborlane WV, Mauras N, Tsalikian E, **Wilson DM**, White NH, the Diabetes Research in Children Network (DirecNet) Study Group. Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. *Pediatric Diabetes* 2013 eprint
- 251.** Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet and the Diabetes Prevention Trial–Type 1 Study Groups (**Wilson DM** is a member of both study groups). The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. *Diabetes Care*. 2013 Sep;36(9):2615-20. PMID: 23818528
- 252.** Marzelli MJ, Mazaika PK, Barnea-Goraly N, Hershey T, Tsalikian E, Tamborlane W, Mauras N, White NH, Buckingham B, Beck RW, Ruedy KJ, Kollman C, Cheng P, Reiss AL; Diabetes Research in Children Network (**Wilson DM** is a member of the DirecNet group). Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. *Diabetes*. 2014 Jan;63(1):343-53 PMID:24170697
- 253.** DeSalvo DJ, Keith-Hynes P, Peyser T, Place J, Caswell K, **Wilson DM**, Harris B, Clinton P, Kovatchev B, Buckingham B. Remote glucose monitoring in camp setting reduces the risk of nocturnal hypoglycemia. *Diab Tech Ther* 16:1, 2014
- 254.** Robinson TN, Matheson D, Desai M, **Wilson DM**, Weintraub DL, Haskell WL, McClain A, McClure S, Banda JA, Sanders LM, Haydel KF, Killen JD. Family, Community and Clinic Collaboration to Treat Overweight and Obese Children: Stanford GOALS -- a Randomized Controlled Trial of a Three-Year, Multi-Component, Multi-Level, Multi-Setting Intervention. *Contemporary Clinical Trials* Contemporary Clinical Trials 36 (2013) 421–435 PMID: 24028942
- 255.** Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; The Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups (**Wilson DM** is a member of both study groups). The Acceleration of the Loss of the First-Phase Insulin Response during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. *Diabetes*. 2013 Jul 17. [Epub ahead of print] PMID: 23863814
- 256.** Weinberg A, Boulware D, Dighero B, Orban T; the Type 1 Diabetes TrialNet Abatacept Study Group (**Wilson DM** is a member of this study group). Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes. *Vaccine*. 2013 Aug 17. doi:pii: S0264-410X(13)01084-0. 10.1016/j.vaccine.2013.07.086. [Epub ahead of print] PMID: 23962535
- 257.** Krischer JP; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the study group) The use of intermediate endpoints in the design of type 1 diabetes prevention trials. *Diabetologia*. 2013 Sep;56(9):1919-24. doi: 10.1007/s00125-013-2960-7. Epub 2013 Jun 7. PMID: 23744306
- 258.** Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, Dimeglio LA, Bremer AA, Slover R, Tamborlane WV; Diabetes Research in Children Network (DirecNet)

- and Type 1 Diabetes TrialNet Study Groups. (**Wilson DM** is a member of both Study Groups) Effectiveness of Early Intensive Therapy on β -Cell Preservation in Type 1 Diabetes. *Diabetes Care*. 2013 Oct 15. [Epub ahead of print] PMID: 24130350
- 259.** DeSalvo DJ, Keith-Hynes P, Peyser T, Place J, Caswell K, **Wilson DM**, Harris B, Clinton P, Kovatchev B, Buckingham BA. Remote Glucose Monitoring in Camp Setting Reduces the Risk of Prolonged Nocturnal Hypoglycemia, *Diabetes Technol Ther*. 2014 Jan;16(1):1-7 PMID:24168317
- 260.** Patel PF, Benasi K, Ferrari G, Evans MG, Shanmugham S, **Wilson DM**, Buckingham BA. Randomized Trial of Infusion Set Function: Steel Versus Teflon. *Diab Tech Ther e-published* Oct 2013 *Diabetes Technol Ther*. 2014 Jan;16(1):15-9 PMID: 24090124
- 261.** Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Russell WE, Schatz D, Wherrett D, **Wilson DM**, Krischer JP, Skyler JS, the Type 1 Diabetes TrialNet Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: Follow-up One Year After Cessation of Treatment. *Diabetes Care*, December 2, 2013 Epub ahead of print. PMID 24296850
- 262.** Barnea-Goraly N, Raman M, Mazaika P, Marzelli M, Hershey T, Weinzimer SA, Aye T, Buckingham B, Mauras N, White NH, Fox LA, Tansey M, Beck RW, Ruedy KJ, Kollman C, Cheng P, Reiss AL; for the Diabetes Research in Children Network (DirecNet)* (**Wilson DM** is a member of the study group). Alterations in White Matter Structure in Young Children With Type 1 Diabetes. *Diabetes Care*. 2013 Dec 6. [Epub ahead of print] PMID: 24319123
- 263.** Marzelli MJ, Mazaika PK, Barnea-Goraly N, Hershey T, Tsalikian E, Tamborlane W, Mauras N, White NH, Buckingham B, Beck RW, Ruedy KJ, Kollman C, Cheng P, Reiss AL; Diabetes Research in Children Network (DirecNet). (**Wilson DM** is a member of the study group). Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. *Diabetes*. 2014 Jan;63(1):343-53. doi: 10.2337/db13-0179. Epub 2013 Oct 29. PMID: 24170697
- 264.** Barnea-Goraly N, Weinzimer SA, Ruedy KJ, Mauras N, Beck RW, Marzelli MJ, Mazaika PK, Aye T, White NH, Tsalikian E, Fox L, Kollman C, Cheng P, Reiss AL; Diabetes Research in Children Network (**Wilson DM** is a member of this Network). High success rates of sedation-free brain MRI scanning in young children using simple subject preparation protocols with and without a commercial mock scanner--the Diabetes Research in Children Network (DirecNet) experience. *Pediatr Radiol*. 2014 Feb;44(2):181-6 PMID:24096802
- 265.** Sherr J, Tsalikian E, Fox L, Buckingham B, Weinzimer S, Tamborlane WV, White NH, Arbelaez AM, Kollman C, Ruedy KJ, Cheng P, Beck RW; Diabetes Research in Children Network (**Wilson DM** is a member of this Network). Evolution of abnormal plasma glucagon responses to mixed-meal feedings in youth with type 1 diabetes during the first 2 years after diagnosis. *Diabetes Care*. 2014 Jun;37(6):1741-4 PMID:24696460
- 266.** Englert K, Ruedy K, Coffey J, Caswell K, Steffen A, Levandoski L; Diabetes Research in Children (DirecNet) Study Group (**Wilson DM** is a member of this Network). Skin and adhesive issues with continuous glucose monitors: a sticky situation. *J Diabetes Sci Technol*. 2014 Jul;8(4):745-51. doi: 10.1177/1932296814529893. Epub 2014 Apr 24. PMID: 24876416

- 267.** Cato MA, Mauras N, Ambrosino J, Bondurant A, Conrad AL, Kollman C, Cheng P, Beck RW, Ruedy KJ, Aye T, Reiss AL, White NH, Hershey T; Diabetes Research in Children Network (DirecNet) (**Wilson DM** is a member of this Network). Cognitive functioning in young children with type 1 diabetes. *J Int Neuropsychol Soc.* 2014 Feb;20(2):238-47 PMID: 24512675
- 268.** Pescovitz M, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JP, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, **Wilson DM**, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte Depletion with Rituximab and Beta-Cell Function: Two-Year Results. *Diabetes Care* 2014;37:453-459. PMID 24026563, PMCID: PMC3898764.
- 269.** Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; the Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. (**Wilson DM** is a member of these Networks). Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes. *Diabetes Care* 2014;37:979-984. PMID 24550217, PMCID: PMC3964487.
- 270.** Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP, and the DPT-1 Study Group. (**Wilson DM** is a member of this Network). Distribution of C-Peptide and its Determinants in North American Children at Risk for Type 1 Diabetes. *Diabetes Care* 2014;37:1959-1965. PMID 24760262, PMCID: PMC4067394.
- 271.** Stenerson M, Cameron F, **Wilson DM**, Harris B, Payne S, Bequette BW, Buckingham BA. The impact of accelerometer and heart rate data on hypoglycemia mitigation in type 1 diabetes. *J. Diabetes Sci. Technol*, 2014;8(1):64-69. PMID:24876539
- 272.** Zisser H, Renard E, Kovatchev B, Cobelli C, Avogaro A, Nimri R, Magni L, Buckingham BA, Chase HP, Doyle FJ 3rd, Lum J, Calhoun P, Kollman C, Dassau E, Farret A, Place J, Breton M, Anderson SM, Dalla Man C, Del Favero S, Bruttomesso D, Filippi A, Scotton R, Phillip M, Atlas E, Muller I, Miller S, Toffanin C, Raimondo DM, De Nicolao G, Beck RW; Control to Range Study Group (Wilson DM is a member of this study group) Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites. *Diabetes Technol Ther.* 2014 Oct;16(10):613-22. doi: 10.1089/dia.2014.0066. Epub 2014 Jul 8. PMID: 25003311 PMCID: PMC4183913
- 273.** Ly TT, Breton MD, Keith-Hynes P, De Salvo D, Clinton P, Benassi K, Mize B, Chernavsky D, Place J, **Wilson DM**, Kovatchev BP, Buckingham BA. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes cAMP. *Diabetes Care.* 2014 Aug;37(8):2310-6 PMID:2487984 PMCID: PMC4179507
- 274.** DeSalvo DJ, Shanmugham S, Ly TT, **Wilson DM**, Buckingham BA. Accuracy evaluation of blood glucose monitoring systems in children on overnight closed-loop control. *J Diabetes Sci Technol.* 2014 Sep;8(5):969-73 PMID:24876427
- 275.** Cameron F, Niemeyer G, **Wilson DM**, Bequette BW, Benassi KS, Clinton P, Buckingham BA. Inpatient Trial of an Artificial Pancreas Based on Multiple Model Probabilistic Predictive

Control with Repeated Large Unannounced Meals, Diabetes Technology & Therapeutics. November 2014, 16(11): 728-734 PMID: 25259939 PMCID: PMC420124

- 276.** Beam CA, Gitelman SE, Palmer J and the Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of this Network) Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies. Diabetes 2014;63:3120-3127. PMID 24722251, PMCID: PMC4141373.
- 277.** Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L, Peakman M, and the Type 1 Diabetes TrialNet Abatacept Study Group (**Wilson DM** is a member of this Network). Reduction in CD4 Central Memory T-cell subset in Co-Stimulation Modulator Abatacept-Treated Patients with Recent-Onset Type 1 Diabetes is Associated with Slower C-Peptide Decline. Diabetes 2014;63:3449-3457. PMID 24834977, PMCID: PMC4171657 (available 10/1/15).
- 278.** Baysal N, Cameron F, Buckingham BA, **Wilson DM**, Chase HP, Maahs DM, Bequette BW for the In Home Closed-Loop Study Group (IHCL), A Novel Method to Detect Pressure-Induced Sensor Attenuations (PISA) in an Artificial Pancreas, Journal of Diabetes Science and Technology 2014, Vol. 8(6) 1091–1096 PMID: 25316716
- 279.** Mauras N, Mazaika P, Buckingham B, Weinzimer S, White N, Tsalikian E, Hershey T, Cato A, Cheng P, Kollman C, Beck R, Ruedy K, Aye, T, Fox L, Arbelaez A, **Wilson D**, Tansey M, Tamborlane W, Peng D, Marzelli M, Winer K, Reiss A. Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children with Type 1 Diabetes: Association with Hyperglycemia. Diabetes. 2015 May;64(5):1770-9. doi: 10.2337/db14-1445. Epub 2014 Dec 8 PMID: 25488901 PMCID: PMC4407847
- 280.** Maahs DM, Calhoun P, Buckingham BA, Chase HP, Hramiak I, Lum J, Cameron F, Bequette BW, Aye T, Paul T, Slover R, Wadwa RP, **Wilson DM**, Kollman C, Beck RW; In Home Closed Loop Study Group A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes.. Diabetes Care. 2014 Jul;37(7):1885-91. doi: 10.2337/dc13-2159. Epub 2014 May 7 PMID: 24804697
- 281.** Tansey M, Beck R, Ruedy K, Tamborlane W, Cheng P, Kollman C, Fox L, Weinzimer S, Mauras N, White NH, Tsalikian E and for the Diabetes Research in Children Network (DirecNet) (**Wilson DM** is a member of the study group). Persistently high glucose levels in young children with type 1 diabetes. Pediatric Diabetes 2014 10.1111/pedi.12248 PMID: 25496062 PMCID:PMC4465416
- 282.** **Wilson DM**, Calhoun P, Maahs MA, Chase HP, Messer L, Buckingham BA, Aye T, Clinton P, Hramiak I, Kollman C, Beck RW for the In Home Closed Loop Study Group Factors Associated With Nocturnal Hypoglycemia in at Risk Adolescents and Young Adults with Type 1 Diabetes, Diabetes Technology and Therapeutics 2015 17(6):385-91. PMID:25761202 PMCID: PMC4432491
- 283.** Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; and the Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups (**Wilson DM** is a member of both these study groups) The Development and Utility of a Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months, Diabetes Care. 2015 Mar 10.. [Epub ahead of print] PMID: 25758770 PMCID: PMC4302258

- 284.** Stenerson M, Cameron F, Payne SR, Payne SL, Ly TT, **Wilson DM**, Buckingham BA3. The impact of accelerometer use in exercise-associated hypoglycemia prevention in type 1 diabetes J Diabetes Sci Technol. 2015 Jan; 9(1):80-5. doi:10.1177/ 1932296814551045. Epub 2014 Sep 17. PMID: 25231116 PMCID: PMC4495548
- 285.** Bollyky JB1, Xu P, Butte AJ, **Wilson DM**, Beam CA, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective. Diabetes Metab Res Rev. 2015 Feb 17. doi: 10.1002/dmrr.2643. PMID: 25689602
- 286.** Shah S, **Wilson DM**, Bachrach LK. Large Doses of Vitamin D Fail to Increase 25-Hydroxyvitamin D Levels or to Alter Cardiovascular Risk Factors in Obese Adolescents: A Pilot Study. J Adolesc Health. 2015 Apr 11. pii: S1054-139. [Epub ahead of print] PMID: 25873553
- 287.** Yu W, Jiang N, Ebert PJR, Kidd BA, Müller S, Lund PJ, Juang J, Adachi K, Tse T, Birnbaum ME, Newell EW, **Wilson DM**, Grotenbreg GM, Valitutti S, Quake SR, Davis MM. Clonal Deletion Prunes but Does Not Eliminate Self-Specific $\alpha\beta$ CD8+ T Lymphocytes Immunity, Volume 42, Issue 5, 19 May 2015, Pages 929-941
- 288.** Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Raffkin LE, Matheson D, Herold KC, Mahon J, Palmer JP, the Diabetes Type 1 TrialNet & Diabetes Prevention Trial-Type 1 Study Groups (**Wilson DM** is a member of both these study groups). A New Approach for Diagnosing Type 1 Diabetes in Autoantibody Positive Relatives of Patients with Type 1 Diabetes Based on Prediction & Natural History. Diabetes Care 2015;38:271-276. PMID 25519451, PMCID: PMC4302258 (available 2/1/16).
- 289.** Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J, Rewers M, Yu L, and the Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of this study group). Electrochemiluminescence Assays for Insulin and Glutamic Acid Decarboxylase Autoantibodies Improve Prediction of Type 1 Diabetes Risk. Diabetes Technol Ther 2015;17:119-127, PMID 25562486, PMCID: PMC4321773 (available 2/1/16),
- 290.** Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP, and the Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of this study group).. Beta Cell Death and Dysfunction during Type 1 Diabetes Development in At-risk Individuals. J Clin Invest 2015;125:1163-1173, PMID 25642774, PMCID: 4362259 (available 6/2/15)
- 291.** DiMeglio LA, Cheng P, Beck RW, Kollman C, Ruedy KJ, Slover R, Aye T, Weinzimer SA, Bremer AA, Buckingham B for the Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of both these study groups). Changes in Beta Cell Function during the Proximate Post-Diagnosis Period in Persons with Type 1 Diabetes. Pediatric Diabetes 2015; Feb 27 Epub ahead of print. PMID 25720763, PMCID: PMC4551616 (available 8/27/16).
- 292.** Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R, Bremer AA, Fuqua J, Tamborlane W, for the Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups (**Wilson DM** is a member of both these study groups). CGM Measured Glucose Values Have a Strong Correlation with C-

peptide, A1c, and IDAAC, But Do Poorly in Predicting C-peptide Levels in the Two Years Following Onset of Diabetes. *Diabetologia* 2015;58:1167-1174. PMID 25773405, PMCID: PMC4416994 (available 6/1/16)

- 293.** Sosenko JM, Skyler JS, Palmer JP, the Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups (**Wilson DM** is a member of both these study groups). The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS). *Curr Diab Rep* 2015;15:626, PMID 26077017, PMCID in process.
- 294.** Bingley PJ, Rafkin L, Matheson D, Steck A Yu L, Henderson C, Beam C, Boulware D, and the Type 1 Diabetes Trialnet Study Group (**Wilson DM** is a member of this study group). Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: a Feasibility Study. *Diabetes Technol Ther* 2015 Sep 16 Epub ahead of print. PMID 26375197, PMCID PMC as supplied by Publisher
- 295.** Loechelt B, Green M, Gottlieb P, Blumberg E, Weinberg A, Quinlan S, Baden L, Marks J, Type 1 Diabetes TrialNet (**Wilson DM** is a member of this study group). Screening and Monitoring of Infectious Complications when Immunosuppression Agents are Studied in the Treatment of Autoimmune Disorders. *J Pediatric Infect Dis Soc* 2015;4:198-204, (2014; June 26 Epub ahead of print), PMID 26336066, PMCID PMC4554203 (available 9/1/16).
- 296.** Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of this study group). Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. *Diabetes Care*. 2015 Oct;38(10):1975-85. doi: 10.2337/dc15-1429. PMID: 26404927
- 297.** Lee P, Lustig RH, Lenders C, Baillargeon J, **Wilson DM** for the Glaser Research Network Obesity Study Group. Insulin-like growth factor-binding protein-1 predicts insulin sensitivity and insulin area-under-the-curve in obese, non-diabetic adolescents, *Endocrine Practice* 2016 Feb;22(2):136-42. doi: 10.4158/EP15885.OR. Epub 2015 Oct 20. PMID: 26484407
- 298.** Mazaika PK, Weinzimer SA, Mauras N, Buckingham B, White NH, Tsalikian E, Hershey T, Cato A, Aye T, Fox L, **Wilson DM**, Tansey M, Tamborlane W, Peng D, Raman M, Marzelli M, Reiss AL, for the Diabetes Research in Children Network. Variations in brain volume and growth in young children with type 1 diabetes. *Diabetes*. 2016 Feb;65(2):476-85. doi: 10.2337/db15-1242. Epub 2015 Oct 28. PMID: 26512024
- 299.** Buckingham BA, Raghinaru D, Cameron F, Bequette BW, Chase HP, Maahs DM, Slover R, Wadwa RP, **Wilson DM**, Ly T, Aye T, Hramiak I, Clarson C, Stein R, Gallego PH, Lum J, Sibayan J, Kollman C, Beck RW; In Home Closed Loop Study Group. Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis. *Diabetes Care*. 2015 Jul;38(7):1197-204. doi: 10.2337/dc14-3053. Epub 2015 Jun 6. Erratum in: *Diabetes Care*. 2015 Sep;38(9):1813. PMID: 26049549
- 300.** Messer LH, Calhoun P, Buckingham B, **Wilson DM**, Hramiak I, Ly TT, Driscoll M, Clinton P, Maahs DM; In Home Closed Loop Study Group In-home nighttime predictive low glucose suspend experience in children and adults with type 1 diabetes. *Pediatr Diabetes*. 2016 Apr 29. doi: 10.1111/pedi.12395. [Epub ahead of print] PMID: 27125223

301. Crossen SS, **Wilson DM**, Saynina O, Sanders LM. Outpatient Care Preceding Hospitalization for Diabetic Ketoacidosis. *Pediatrics*. 2016;137(6):e20153497
302. Ly TT, Keenan DB, Anirban R, Han J, Grosman B, Cantwell M, Kurtz N, von Eyben R, Clinton P, **Wilson DM**, Buckingham BA. Automated overnight closed-loop control using a proportional-integral-derivative algorithm with insulin feedback in children and adolescents with type 1 diabetes at diabetes camp *Diabetes Technol Ther*. *Diabetes Technol Ther*. 2016 Jun;18(6):377-84 PMID: 27183197
303. Steck AK, Fouts A, Miao D, Zhao Z, Dong F, Sosenko J, Gottlieb P, Rewers MJ, Yu L, and the TrialNet Study Group ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study (**Wilson DM** is a member of this study group) *Diabetes Technology & Therapeutics*, Vol. 18, No. 7, July 2016: 410-414. PMID: 26991969 PMCID: PMC4931768
304. Calhoun PM, Buckingham BA, Maahs DM, Hramiak I, **Wilson DM**, Aye T, Clinton P, Chase P, Messer L, Kollman C, Beck RW, Lum J; In Home Closed Loop Study Group. Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes. *J Diabetes Sci Technol*. 2016 Nov 1;10(6):1216-1221. PMID: 27207890
305. Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus. *J Immunol*. 2016 Sep 21. pii: 1600197. [Epub ahead of print] PMID: 27655844
306. Narsale A, Moya R, Robertson HK; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group), Davies JD. Data on correlations between T cell subset frequencies and length of partial remission in type 1 diabetes. *Data Brief*. 2016 Aug 6;8:1348-51. doi: 10.1016/j.dib.2016.07.059. eCollection 2016 Sep. PMID: 27579340
307. Fouts A, Pyle L, Yu L, Miao D, Michels A, Krischer J, Sosenko J, Gottlieb P, Steck AK; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects? *Diabetes Care*. 2016 Oct;39(10):1738-44. doi: 10.2337/dc16-0302. Epub 2016 Jul 25. PMID: 27456836
308. Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. *Diabetes Care*. 2016 Oct;39(10):1664-70. doi: 10.2337/dc16-0360. Epub 2016 Jul 15. PMID: 27422577
309. Xu P, Krischer JP; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis. *Diabetes Care*. 2016 Jun;39(6):1036-44. doi: 10.2337/dc15-2292. Epub 2016 Apr 12. PMID: 27208341
310. Moya R, Robertson HK, Payne D, Narsale A, Koziol J; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group), Davies JD. A pilot study

- showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes. *Clin Immunol*. 2016 May;166-167:72-80. doi: 10.1016/j.clim.2016.04.012. Epub 2016 Apr 22. PMID: 27114212
- 311.** Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. *Diabetologia*. 2016 Jun;59(6):1186-95. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19. PMID: 26995649
- 312.** Steck AK, Fouts A, Miao D, Zhao Z, Dong F, Sosenko J, Gottlieb P, Rewers MJ, Yu L; TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. *Diabetes Technol Ther*. 2016 Jul;18(7):410-4. doi: 10.1089/dia.2015.0316. Epub 2016 Mar 18. PMID 26991969
- 313.** Bundy B, Krischer JP; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). A Model Based Approach to Sample Size Estimation in Recent Onset Type 1 Diabetes. *Diabetes Metab Res Rev*. 2016 Mar 16. doi: 10.1002/dmrr.2800. [Epub ahead of print] PMID: 26991448
- 314.** Triolo TM, Maahs DM, Pyle L, Slover R, Buckingham B, Cheng P, DiMeglio LA, Bremer AA, Weinzimer SA, Chase HP; Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group and the DirecNet Group). Effects of Frequency of Sensor-Augmented Pump Use on HbA1c and C-Peptide Levels in the First Year of Type 1 Diabetes. *Diabetes Care*. 2016 Apr;39(4):e61-2. doi: 10.2337/dc15-2201. Epub 2016 Feb 19. PMID: 26895885
- 315.** Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L, Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum C, Eisenbarth GS, Sosenko JM; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. *Diabetes*. 2016 Apr;65(4):1109-19. doi: 10.2337/db15-1105. Epub 2016 Jan 28. PMID: 26822082
- 316.** Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ; Type 1 Diabetes TrialNet Canakinumab Study Group (**Wilson DM** is a member of the TrialNet Study Group), Mandrup-Poulsen T; AIDA Study Group, Hessner MJ. Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. *Eur J Immunol*. 2016 Apr;46(4):1030-46. doi: 10.1002/eji.201546005. Epub 2016 Jan 21. PMID: 26692253
- 317.** Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. *Diabetologia*. 2016 Mar;59(3):542-9. doi: 10.1007/s00125-015-3830-2. Epub 2015 Dec 16. PMID: 26676824

- 318.** Hosseini SM, Mazaika P, Mauras N, Buckingham B, Weinzimer SA, Tsalikian E, White NH, Reiss AL; Diabetes Research in Children Network (DirecNet) (**Wilson DM** is a member of the DirecNet Study Group). Altered Integration of Structural Covariance Networks in Young Children With Type 1 Diabetes. *Hum Brain Mapp.* 2016 Jun 24. doi: 10.1002/hbm.23293. [Epub ahead of print] PMID: 27339089
- 319.** Saggat M, Tsalikian E, Mauras N, Mazaika P, White NH, Weinzimer S, Buckingham BA, Hershey T, Reiss AL for the Diabetes Research in Children Network* (**Wilson DM** is a member of this Network) Compensatory Hyperconnectivity in Developing Brains of Young Children With Type 1 Diabetes. *Diabetes.* 2017 Mar;66(3):754-762 PMID:27702833 PMCID:PMC5319714
- 320.** El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, **Wilson DM**, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. *Lancet.* 2017 Jan 28;389(10067):369-38] PMID: 28007348
- 321.** Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group). GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis. *Diabetologia.* 2017 Jan;60(1):43-49. Epub 2016 Oct 4 PMID:27704166
- 322.** Spaic T, Driscoll M, Raghinaru D, Buckingham BA, **Wilson DM**, Clinton P, Chase HP, Maahs DM, Forlenza GP, Jost E, Hramiak I, Paul T, Bequette BW, Cameron F, Beck RW, Kollman C, Lum JW, Ly TT. Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes. In-Home Closed-Loop (IHCL) Study Group. *Diabetes Care.* 2017 Mar;40(3):359-366. doi: 10.2337/dc16-1794. Epub 2017 Jan 18. PMID:28100606
- 323.** Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ, Rodriguez H, Moran A, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member to the TrialNet Study Group) Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? *Diabetes Care.* 2017 May;40(5):698-701. doi: 10.2337/dc16-2331. Epub 2017 Feb 15.
- 324.** Forlenza GP, Raghinaru D, Cameron F, Bequette BW, Chase HP, Wadwa RP, Maahs DM, Jost E, Ly TT, **Wilson DM**, Norlander L, Ekhlaspour L, Min H, Clinton P, Njeru N, Lum JW, Kollman C, Beck RW, Buckingham BA. Predictive hyperglycemia and hypoglycemia minimization: In-home double blind randomized controlled evaluation in children and young adolescents. *Pediatr Diabetes.* *Pediatr Diabetes.* 2018 May;19(3):420-428. doi: 10.1111/pedi.12603. Epub 2017 Nov 20. PMID: 29159870
- 325.** Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group (**Wilson DM** is a member of the TrialNet Study Group), Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial, *JAMA.* 2017;318(19):1891-1902. doi:10.1001/jama.2017.17070 PMID:29164254 PMCID: PMC5798455

- 326.** Ferrara CT, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Wentworth JM, Moran A, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. *J Clin Endocrinol Metab.* 2017 Dec 1;102(12):4596-4603. doi: 10.1210/jc.2017-01 PMID: 29092051
- 327.** Ismail HM, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. *Diabetologia.* 2018 Jan;61(1):84-92. doi: 10.1007/s00125-017-4453-6. Epub 2017 Sep 27. PMID:28956083
- 328.** Nathan BM, Boulware D, Geyer S, Atkinson MA, Colman P, Goland R, Russell W, Wentworth JM, **Wilson DM**, Evans-Molina C, Wherrett D, Skyler JS, Moran A, Sosenko JM; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. *Diabetes Care.* 2017 Nov;40(11):1494-1499. doi: 10.2337/dc17-0916. Epub 2017 Aug 31. PMID:28860125
- 329.** Steck AK, Xu P, Geyer S, Redondo MJ, Antinozzi P, Wentworth JM, Sosenko J, Onengut-Gumuscu S, Chen WM, Rich SS, Pugliese A; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group). Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes? *J Clin Endocrinol Metab.* 2017 Aug 1;102(8):2873-2880. doi: 10.1210/jc.2016-4003. PMID:28520980
- 330.** Liu Y, Rafkin LE, Matheson D, Henderson C, Boulware D, Besser REJ, Ferrara C, Yu L, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group) Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study. *Diabet Med.* 2017 Jul;34(7):934-937. doi: 10.1111/dme.13338. Epub 2017 Mar 8. PMID:28226181
- 331.** Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ, Rodriguez H, Moran A, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group). Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? *Diabetes Care.* 2017 May;40(5):698-701. doi: 10.2337/dc16-2331. Epub 2017 Feb 15. PMID:28202550
- 332.** Forlenza GP, Raghinaru D, Cameron F, Wayne Bequette B, Peter Chase H, Paul Wadwa R, Maahs DM, Jost E, Ly TT, Wilson DM, Norlander L, Ekhlaspour L, Min H, Clinton P, Njeru N, Lum JW, Kollman C, Beck RW, Buckingham BA; In-Home Closed-Loop (IHCL) Study Group. Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescents. *Pediatr Diabetes.* 2018 May;19(3):420-428. doi: 10.1111/pedi.12603. Epub 2017 Nov 20. PMID: 29159870
- 333.** Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C, Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group).. Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. *J Clin*

Endocrinol Metab. 2017 Aug 1;102(8):2881-2886. doi: 10.1210/jc.2017-00569. PMID: 28531305 490.

- 334.** Redondo MJ, Geyer S, Steck AK, Sosenko J, Anderson M, Antinozzi P, Michels A, Wentworth J, Xu P, Pugliese A; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. *Diabetes Care*. 2018 Feb;41(2):311-317. doi: 10.2337/dc17-0961. Epub 2017 Oct 12. PMID:29025879
- 335.** Sanda S; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group). Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. *Pediatr Diabetes*. 2018 Mar;19(2):271-276. doi: 10.1111/pedi.12542. Epub 2017 Jul 14. PMID:28707353
- 336.** Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, **Wilson DM**, Greenbaum CJ and the Type 1 Diabetes TrialNet ATG-GCSF Study Group. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. *Diabetes Care* published ahead of print July 16, 2018, doi:10.2337/dc18-0494 PMID:30967424
- 337.** Pahalad P, Addala A, Buckingham B, **Wilson, DM**, and Maahs, DM. Sustained Continuous Glucose Monitor Use in Low-Income Youth with Type 1 Diabetes Following Insurance Coverage Supports Expansion of Continuous Glucose Monitor Coverage for All. *Diabetes Technology & Therapeutics* Volume 20, Number 9, 2018 PMID: 30020810 PMCID: PMC6421989
- 338.** Vecchio F, Lo Buono N, Stabilini A, Nigi L, Dufort MJ, Geyer S, Rancoita PM, Cugnata F, Mandelli A, Valle A, Leete P, Mancarella F, Linsley PS, Krogvold L, Herold KC, Larsson HE, Richardson SJ, Morgan NG, Dahl-Jørgensen K, Sebastiani G, Dotta F, Bosi E; DRI_Biorepository Group; Type 1 Diabetes TrialNet Study Group, (**Wilson DM** is a member of the TrialNet Study Group) Battaglia M. Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. *JCI Insight*. 2018 Sep 20;3(18). pii: 122146. doi: 10.1172/jci.insight.122146. [Epub ahead of print] PMID: 30232284
- 339.** Cabrera SM, Engle S, Kaldunski M, Jia S, Geoffrey R, Simpson P, Szabo A, Speake C, Greenbaum CJ; Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group (**Wilson DM** is a member of the TrialNet Study Group), Chen YG, Hessner MJ. Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes. *Diabetologia*. 2018 Nov;61(11):2356-2370. doi: 10.1007/s00125-018-4708-x. Epub 2018 Aug 30. PMID:30167736
- 340.** Wentworth JM, Bediaga NG, Giles LC, Ehlers M, Gitelman SE, Geyer S, Evans-Molina C, Harrison LC; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study Group); Immune Tolerance Network Study Group. Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables. *Diabetologia*. 2018 Aug 30. doi: 10.1007/s00125-018-4722-z. [Epub ahead of print] PMID: 30167735
- 341.** Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group) Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes.

Diabetes Care. 2018 Jul 30. pii: dc180288. doi: 10.2337/dc18-0288. [Epub ahead of print] PMID: 30061316

- 342.** Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P, Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. *Diabetes Care*. 2018 Sep;41(9):1887-1894. doi: 10.2337/dc18-0087. Epub 2018 Jul 12. PMID:30002199
- 343.** Redondo MJ, Steck AK, Sosenko J, Anderson M, Antinozzi P, Michels A, Wentworth JM, Atkinson MA, Pugliese A, Geyer S; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. *Diabetes Care*. 2018 Dec;41(12):2480-2486. doi: 10.2337/dc18-0861. Epub 2018 Oct 1. PMID: 30275285
- 344.** Foland-Ross LC, Reiss AL, Mazaika PK, Mauras N, Weinzimer SA, Aye T, Tansey MJ, White NH; Diabetes Research in Children Network (DirecNet). (**Wilson DM** is a member of the DirecNet Study Group) Longitudinal assessment of hippocampus structure in children with type 1 diabetes. *Pediatr Diabetes*. 2018 Apr 19. doi: 10.1111/pedi.12683. [Epub ahead of print PMID: 29675980
- 345.** Fox LA, Hershey T, Mauras N, Arbeláez AM, Tamborlane WV, Buckingham B, Tsalikian E, Englert K, Raman M, Jo B, Shen H, Reiss A, Mazaika P; Diabetes Research in Children Network (DirecNet). (**Wilson DM** is a member of the DirecNet Study Group) Persistence of abnormalities in white matter in children with type 1 diabetes. *Diabetologia*. 2018 Jul;61(7):1538-1547. doi: 10.1007/s00125-018-4610-6. Epub 2018 Apr 13. PMID: 29654376
- 346.** Nally LM, Bondy N, Doiev J, Buckingham BA, **Wilson DM**. A Feasibility Study to Detect Neonatal Hypoglycemia in Infants of Diabetic Mothers Using Real-Time Continuous Glucose Monitoring. *Diabetes Technol Ther*. 2019 Apr;21(4):170-176 PMID: 30839229
- 347.** Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, **Wilson DM**, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. *Diabetes*. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9. PMID: 30967424
- 348.** Habib T, Long SA, Samuels PL, Brahmandam A, Tatum M, Funk A, Hocking AM, Cerosaletti K, Mason MT, Whalen E, Rawlings DJ, Greenbaum C, Buckner JH; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group) Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression. *Diabetes*. 2019 Jun;68(6):1240-1250. doi: 10.2337/db18-1081. Epub 2019 Mar 20. PMID: 30894366
- 349.** Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell

- WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study) An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. Group) *N Engl J Med*. 2019 Jun 9. doi: 10.1056/NEJMoa1902226. [Epub ahead of print] PMID: 31180194
- 350.** Acevedo-Calado MJ, Pietropaolo SL, Morran MP, Schnell S, Vonberg AD, Verge CF, Gianani R, Becker DJ, Huang S, Greenbaum CJ, Yu L, Davidson HW, Michels AW, Rich SS, Pietropaolo M; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group) Autoantibodies Directed to a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes. *Diabetes*. 2019 Jun 5. pii: db181351. doi: 10.2337/db18-1351. [Epub ahead of print] PMID:31167877
- 351.** Vaitaitis GM, Rihanek M, Alkanani AK, Waid DM, Gottlieb PA, Wagner DH; Type 1 Diabetes TrialNet Study Group. (**Wilson DM** is a member of the TrialNet Study Group) Biomarker discovery in pre-Type 1 Diabetes; Th40 cells as a predictive risk factor. *J Clin Endocrinol Metab*. 2019 May 7. pii: jc.2019-00364. doi: 10.1210/jc.2019-00364. [Epub ahead of print] PMID: 31063181
- 352.** Aye T, Mazaika PK, Mauras N, Marzelli MJ, Shen H, Hershey T, Cato A, Weinzimer SA, White NH, Tsalikian E, Jo B, Reiss AL; Diabetes Research in Children Network (DirecNet) Study Group. (**Wilson DM** is a member of the DirecNet Study Group) Impact of Early Diabetic Ketoacidosis on the Developing Brain. *Diabetes Care*. 2019 Mar;42(3):443-449. doi: 10.2337/dc18-1405. Epub 2018 Dec 20. PMID: 30573652
- 353.** Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, **Wilson DM**. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop. *Diabetes Care*. 2019 Sep 23. pii: dc190855. doi: 10.2337/dc19-0855. [Epub ahead of print] PMID: 31548247
- 354.** Jacobsen LM, Bocchino L, Evans-Molina C, DiMeglio L, Goland R, **Wilson DM**, Atkinson MA, Aye T, Russell WE, Wentworth JM, Boulware D, Geyer S, Sosenko JM The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.. *Diabetologia*. 2020 Mar;63(3):588-596. doi: 10.1007/s00125-019-05047-w. Epub 2019 Nov 25. PMID: 31768570
- 355.** Cortez F, Gebhart D, Robinson PV, Seftel D, Pourmandi N, Owyong J, Bertozzi CR, **Wilson DM**, Maahs DM, Buckingham BA, Mills JD, Roforth MM, Pittock SJ, McKeon A, Page K, Wolf WA, Sanda S, Speake C, Greenbaum CJ, Tsai CT. Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR. *PLoS One* 2020 Nov 13;15(11):e0242049 PMID: 33186361
- 356.** Foland-Ross LC, Tong G, Mauras N, Cato A, Aye T, Tansey M, White NH, Weinzimer SA, Englert K, Shen H, Mazaika PK, Reiss AL; Diabetes Research in Children Network (DirecNet) (**Wilson DM** is a member of the DirecNet Study Group)). Brain Function Differences in Children With Type 1 Diabetes: A Functional MRI Study of Working Memory. *Diabetes*. 2020 Aug; 69(8):1770-1778. doi: 10.2337/db20-0123. Epub 2020 May 29. PMID: 32471809
- 357.** Tosur M, Cleves MA, Sosenko JM, Libman I, Baidal DA, Balasubramanyam A, Redondo MJ; Type 1 Diabetes TrialNet Study Group (**Wilson DM** is a member of the TrialNet Study). The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type

- 1 Diabetes Diagnosis. *J Clin Endocrinol Metab.* 2020 Dec 1;105(12):e4393-406. doi: 10.1210/clinem/dgaa348. PMID: 32502242
- 358.** Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL, Diabetes Research in Children Network (DirecNet) (**Wilson DM** is a member of the DirecNet Study Group) Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. *Diabetes Care.* 2021 Feb 10;dc202125. Online ahead of print. PMID: 33568403
- 359.** Robinson TN, Matheson D, **Wilson DM**, Weintraub DL, Banda JA, McClain A, Sanders LM, Haskell WL, Haydel KF, Kapphahn KI, Pratt C, Truesdale KP, Stevens J, Desai M. A community-based, multi-level, multi-setting, multi-component intervention to reduce weight gain among low socioeconomic status Latinx children with overweight or obesity: The Stanford GOALS randomized controlled trial www.thelancet.com/diabetes-endocrinology Published online April 29, 2021 [https://doi.org/10.1016/S2213-8587\(21\)00084-X](https://doi.org/10.1016/S2213-8587(21)00084-X) *Lancet Diabetes Endocrinol* 2021 Jun;9(6):336-349 PMID: 33933181
- 360.** Cortez FdJ, Gebhart D, Tandel D, Robinson PV, Seftel D, **Wilson DM**, Maahs DM, Buckingham BA, Kevin KWP, Tsai C. Automation of a Multiplex Agglutination-PCR (ADAP) Type 1 Diabetes (T1D) Assay for the Rapid Analysis of Islet Autoantibodies (DOI: 10.1177/24726303211039174/ ID: TECH-21-0020.R2). *SLAS Technology* *SLAS Technol.* 2022 Feb;27(1):26-31. PMID: 35058202
- 361.** Carla J Greenbaum¹, Elisavet Serti², Katharina Lambert¹, Lia J Weiner³, Sai Kanaparthi², Sandra Lord¹, Stephen E Gitelman⁴, **Darrell M Wilson**⁵, Jason L Gaglia⁶, Kurt J Griffin⁷, William E Russell⁸, Philip Raskin⁹, Antoinette Moran¹⁰, Steven M Willi¹¹, Eva Tsalikian¹², Linda A DiMeglio¹³, Kevan C Herold¹⁴, Wayne V Moore¹⁵, Robin Goland¹⁶, Mark Harris^{17,23}, Maria E Craig¹⁸, Desmond A Schatz¹⁹, David A Baidal²⁰, Henry Rodriguez²¹, Kristina M Utzschneider²², Hendrik J Nel²³, Carol L Soppe², Karen D Boyle³, Karen Cerosaletti¹, Lynette Keyes-Elstein³, S Alice Long¹, Ranjeny Thomas²³, James G McNamara²⁴, Jane H Buckner¹, and Srinath Sanda^{2,4} for the ITN058AI EXTEND Study Team, IL-6 receptor blockade does not slow β -cell loss in new onset type 1 diabetes, *JCI* 2021 PMID: 34747368
- 362.** Michael G Voss 1, David D Cuthbertson 2, Mario M Cleves 2, Ping Xu 2, Carmella Evans-Molina 3, Jerry P Palmer 4, Maria J Redondo 5, Andrea K Steck 6, Markus Lundgren 7, Helena Larsson 7, Wayne V Moore 8, Mark A Atkinson 9, Jay M Sosenko 10, Heba M Ismail, DPT-1 and TrialNet Study Groups; DPT-1 and TrialNet Study Groups Investigators (**Wilson DM** is a member of the DPT-1 and TrialNet Study).:Time to Peak Glucose and Peak C-peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts. *Diabetes Care* 2021 Oct;44(10):2329-2336. doi: 10.2337/dc21-0226. PMID: 34362815
- 363.** Gregory P Forlenza 1, Tim Vigers 2 3, Cari Berget 4, Laurel Messer 5, Rayhan Adi Lal 6 7, Marina Basina 8 9, David M Maahs 10, Korey Hood 11 12, Bruce A Buckingham 13, **Darrell M Wilson** 14, R Paul Wadwa 15, Kimberly A Driscoll 16, Laura Pyle; Predicting Success with a First-Generation Hybrid Closed Loop Artificial Pancreas System among Children, Adolescents, and Young Adults with Type 1 Diabetes: a Model Development and Validation Study” *Diabetes Technol Ther.* 2022 Mar;24(3):157-166. Online ahead of print. PMID: 34780306

- 364. Darrell M. Wilson*1**, MD; Susan L. Pietropaolo*2, Maria Acevedo-Calado*2, PhD; Shuai Huang³, PhD; Destiny Anyaiwe⁴, PhD; David Scheinker¹, PhD; Andrea K. Steck⁵, MD; Madhuri M. Vasudevan², MD, MPH; Siripoom V. McKay¹¹, MD; Jennifer L. Sherr⁶, MD, PhD; Kevan C. Herold⁷, MD; Jessica L. Dunne⁸, PhD; Carla J. Greenbaum⁹, MD; Sandra M. Lord⁹; Michael J. Haller¹⁰, MD; Desmond A. Schatz¹⁰, MD; Mark A. Atkinson¹⁰, PhD; Patrick W. Nelson⁴, PhD; and Massimo Pietropaolo^{2†}, MD; CGM Metrics Identify Dsglycemic States in Subjects from the TrialNet Pathway to Prevention Study Type 1 Diabetes TrialNet Study Group *Diabetes Care*. 2023 Mar 1;46(3):526-534. doi: 10.2337/dc22-1297. PMID: 36730530 PMID: 36730530
- 365.** William E. Russell, M.D.^{1,2,22.}, Brian N. Bundy, Ph.D.^{2.}, Mark S. Anderson, M.D., Ph.D.^{3.,4.} Laura A. Cooney, Ph.D.^{4...} Stephen E. Gitelman, M.D.^{5.}, Robin S. Goland, M.D.^{6.}, Peter A. Gottlieb, M.D.^{7.}, Carla J. Greenbaum, M.D.^{8.}, Michael J. Haller, M.D.^{9.} Jeffrey P. Krischer, Ph.D.^{2.}, Ingrid M. Libman, M.D.^{10.}, Peter S. Linsley, Ph. D.^{8.}, S. Alice Long, Ph.D.^{8.}, Sandra M. Lord, M.D.^{8.}, Daniel J Moore, M.D., Ph.D.^{11..}, Wayne V. Moore, M.D., Ph.D.^{12.}, Antoinette M. Moran, M.D.^{13.}, Andrew B. Muir, M.D.^{14.}, Phillip Raskin, M.D.^{15.}, Jay S. Skyler, M.D.^{16.}, John M. Wentworth, M.D.^{17.}, Diane K. Wherrett, M.D.^{18.}, **Darrell M. Wilson, M.D.**^{19.}, Anette-Gabriele Ziegler, M.D.^{20.} . Kevan C. Herold, M.D.^{21, 23} and the Type 1 Diabetes TrialNet Study Group* Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk:A Randomized, Double-Masked, Controlled Trial . *Diabetes Care* <https://doi.org/10.2337/dc22-2200> PMID: 36920087
- 366.** Zaharieva DP, Ding V, Addala A, Prahalad P, Bishop F, Hood K, Desai M, Wilson DM, Buckingham BA, Maahs DM. Diabetic ketoacidosis (DKA) at diagnosis in youth with type 1 diabetes (T1D) is associated with a higher hemoglobin A1c even with intensive insulin management. *Diabetes Technol Ther*. 2023 Nov 13. doi: 10.1089/dia.2023.0405. Online ahead of print. PMID: 37955644
- 367.** Ylescupidiez A, Speake C, Pietropaolo SL, Wilson DM, Steck AK, Sherr JL, Gaglia JL, Bender C, Lord S, Greenbaum CJ. OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody-positive individuals. *J Clin Endocrinol Metab*. 2023 Aug 13;dgad472. doi: 10.1210/clinem/dgad472. Online ahead of print Volume 109, Issue 1, January 2024, Pages 57–67,. PMID: 37572381

INVITED ARTICLES

- Wilson DM:** Therapeutic goals in children with diabetes. *Diabetes Dialogue - Diabetes Society of Santa Clara Valley*, 4:1, 1987
- Wilson DM,** Rosenfeld RG: Abnormal growth patterns in children. *Child Care Center* 3:43-44, 1988
- Neely EK, **Wilson DM,** Hintz RL. Response to "Local reactions to depot leuprolide therapy for central precocious puberty" [Letter]. *J Pediatr* 123:335; 1993

4. **Wilson DM:** Diabetes mellitus. in Prober CG, Behrman RE, Cisco J [eds] Nelson Self-Assessment Program, WB Saunders 1995
5. **Wilson DM:** Diabetes Mellitus in Children and Adolescents UPDATE #8 - Nelson's Textbook of Pediatrics, 1995
6. **Wilson DM:** Is Testing for Growth Hormone Release Necessary? Pro vs. Con, *Kidney Int Suppl* 53:s123-5, 1996
7. **Wilson DM:** Regular Monitoring of Bone Age is Not Useful in Children on Growth Hormone Therapy. *Pediatrics* 104:1036-9, 1999
8. **Wilson DM:** Glucose simulators: Ready for Prime Time? (editorial) *Diabetes Technology & the 2013 American Control Conference to be held in Washington, DC, USA. Therapeutics* 1:55-56, 1999
9. **Wilson DM:** Growth Hormone and Hypophosphatemic Rickets. *J Pediat Endocrinol and Metab* 13:993-998, 2000
10. **Wilson DM:** Glucose Meters: Now What?? (editorial) *Diabetes Technology & Therapeutics* 2:231-2, 2000
11. Buckingham B, Bluck B, **Wilson DM:** Intensive Diabetes Management in Pediatric Patients, *Current Diabetes Reports*, 1:11-18, 2001
12. **Wilson DM:** Progress in the Treatment of Childhood Diabetes Mellitus and Obesity. *J Ped Endocrin and Metab* 15:745-749, Suppl 2, 2002
13. Buckingham B, Caswell K, **Wilson DM.** Real-time continuous glucose monitoring. *Curr Opin Endocrinol Diabetes Obes.* 14:288-95, 2007.
14. Baysal N, Cameron F, Buckingham BA, **Wilson DM,** Bequette BW. Detecting Sensor and Insulin Infusion Set Anomalies in an Artificial Pancreas; The 2013 American Control Conference, Washington, DC, USA.
15. **Wilson DM:** Is pump therapy for all with Type 1 diabetes? *Diabetes Technol Ther.* 2016 May;18(5):280-1. doi: 10.1089/dia.2016.0108.PMID: 27159783
16. Chang M, **Wilson DM,** Maahs DM. 50 years ago - Familial Holoprosencephaly with Endocrine Dysgenesis. *J Pediatr.* 2018 Jan;192:98. doi: 10.1016/j.jpeds.2017.07.027. PMID:29246365

CHAPTERS

1. Rosenfeld RG, **Wilson DM,** Bennett A, Hintz RL: Recombinant DNA derived growth hormone is biologically active in humans: In vitro and in vivo studies. in JL Guerigan, ED Branson, AS Outschoorn [eds] *Hormone Drug Proceedings of the FDA-USP Workshop on Drug and Reference Standards for Insulins, Somatotropins, and Thyroid-axis Drugs*, USPC, Rockville, MD, 352-362, 1982

2. Rosenfeld RG, **Wilson DM**, Lee PDK, Hintz RL: Clinical relevance of the somatomedins. in Hintz RL, Underwood LE [eds] Somatomedins and Other Peptides Growth Factors: Relevance to Pediatrics, pp 64-69, Ross Laboratories, 1985
3. **Wilson DM**, Duncan PM, Dornbusch SM, Ritter PL, Rosenfeld RG: The effects of growth on intellectual function in children and adolescents. in Stabler B, Underwood LE [eds] Slow Grows the Child: Psychosocial Aspects of Growth Delay, pp 139-150, Lawrence Erlbaum Associates, New Jersey, 1986
4. **Wilson DM**: Growth abnormalities in diabetes mellitus. In Hintz RL, Rosenfeld RG [eds] Growth Abnormalities, Contemporary Issues in Endocrinology and Metabolism, Vol. 4, Churchill Livingstone, Inc, pp 59-80, 1986
5. **Wilson DM**, Rosenfeld RG: Treatment of Short Stature and Delayed Adolescence. Pediatric Clinics of North America 34:865-878, 1987
6. Hintz RL, **Wilson DM**, Rosenfeld RG: Usefulness of somatomedin C/Insulin-like growth factor levels and response in growth hormone deficiency. in Laron Z, Butenandt O [eds] Future Clinical Use of Growth Hormone, Series Pediatric and Adolescent Endocrinology. S Karger 16:29-36, 1987
7. Rosenfeld RG, Ceda GP, Conover CA, **Wilson DM**, Hoffman AR: Somatomedin action and tissue growth factor receptors. in Robbins R, Melmed S. [eds] Acromegaly, Plenum Press, NY, pp 55-64, 1987
8. Rosenfeld RG, **Wilson DM**, Lee PDK, Hintz RL: Use of somatomedin assays in the evaluation of short stature. NICHD International Workshop on Advances in Research of Human Growth, in: Grave GD, Cassorla FG [eds]. Disorders of Human Growth: Advances in Research and Treatment, pp 82-95 C.G. Thomas, Springfield IL. 1988
9. Wang M, **Wilson DM**, Lee PDK: Serum levels of 25Kda insulin-like growth factor binding in children with insulin-dependent diabetes mellitus. in Hintz RL. [ed] Insulin-like Growth Factor Binding Proteins, pp 39-44, 1989, Elsevier Science Publishers, Amsterdam
10. **Wilson DM**, DeLeon DD, Bakker B, Lamson G, Rosenfeld RG: IGFs and IGF binding proteins in human breast cancer cell lines in Hintz RL. [ed] Insulin-like Growth Factor Binding Proteins, pp 241-246, 1989, Elsevier Science Publishers, Amsterdam
11. **Wilson DM**, Hintz RL, Rosenfeld RG, Frane JW, Sherman B, Johanson AJ: Effects of growth hormone and oxandrolone therapy on carbohydrate metabolism in Turner syndrome. in Rosenfeld RG, Grumbach M. [eds] Turner syndrome, Marcel Dekker, Inc, NY, pp 433-445, 1990
12. **Wilson DM**, Rosenfeld RG: New directions in the diagnosis and treatment of growth failure. in Mazzaferri E, Bar RS, Kreisberg RA, [eds] Advances in Endocrinology and Metabolism, pp 95-128, 1990
13. **Wilson DM**: Hypophosphatemic rickets. in Rosenfeld RG [ed] Highlights of the 3rd International Symposium on Endocrine Disorders, Excerpta Medica, pp 16-17, 1990

14. **Wilson DM**: Rosenfeld RG: Effect of GH and oxandrolone on carbohydrate and lipid metabolism. in Ranke MB, Rosenfeld RG [eds] Turner syndrome: Growth promoting therapies: Proceeding of the 2nd International Symposium on Turner's syndrome, Excerpta Medica, pp 269-274, 1991
15. **Wilson DM**: Clinical Actions of Growth Hormone. Endocrinology and Metabolism Clinics of North America 21:519-537, 1992
16. **Wilson DM**, Alon U: Renal hypophosphatemia. in Alon U, Chan JCM [eds] Phosphate in Pediatric Health and Disease, pp 159-192, CRC Press, Boca Raton, FL, 1993
17. **Wilson DM**: Endocrinology of growth and growth factors. in Gerber L, Byers P, Marini J [eds] Frontiers in Rehabilitation Medicine: Osteogenesis Imperfecta, Connective Tissue Research 31:S3-S7, 1995
18. Rosenthal S, **Wilson DM**: Pediatric Endocrinology. in Rudolph AM, Kamei R [eds] Fundamentals of Pediatrics, Appleton & Lange, Norwalk, CT, 1994
19. **Wilson DM**: Indications for Treatment in [eds] Hintz RL, **Wilson DM**. Puberty... When it comes too soon. A Special Ross Round table on Pediatric Research, Conference in Washington, DC. Ross Products Division, Abbott Laboratories, Columbus OH, 1994
20. **Wilson DM**: Diagnosis of GH Deficiency: GH, IGF, and IGFBP-3, in Proceedings of the 2nd Annual DSL International Scientific Meetings, 1994 (published in 1997)
21. **Wilson DM**: Olney RC, Tyerman G, Lee PDK, Klingensmith GJ, Chan J, Shah B, Shulman DI, Mahoney CP, Kaufman E. GH in X-linked hypophosphatemic rickets - Preliminary results - First Year, in Proceedings of the 3rd Annual DSL International Scientific Meetings, 1995 (published in 1997)
22. Lum CK, **Wilson DM**: Growth hormone therapy in children. In: Contemporary Endocrinology: Hormone Replacement Therapy, Meikle AW (ed), Humana Press Inc., Toronto, NJ, 1999
23. **Wilson DM**: Methods of measuring serum IGF-I. In Assessment of The Growth Hormone/IGF-I Axis In Aging. Endocrinol (in press)
24. **Wilson DM**: Growth hormone therapy in children and adult. In: Contemporary Endocrinology: Hormone Replacement Therapy in Clinical Practice, Meikle AW (ed), Humana Press Inc., Toronto, NJ, 2003
25. Buckingham B, Caswell K, **Wilson DM**. Real-time continuous glucose monitoring, Current Opinions in Endocrinology 2007 Aug;14(4):288-95.
26. Forghani N, **Wilson DM**. Endocrine disorders, Chapter 44, A Practical Guide to Pediatric Emergency Medicine, edited by AMIEVA-WANG et al, Cambridge Press, 2011
27. Park JG, N. Amieva-Wang E, Turchi C, Forghani N, and **Wilson DM**. Neonatal emergencies, Chapter 157, A Practical Guide to Pediatric Emergency Medicine, edited by AMIEVA-WANG et al, Cambridge Press, 2011

28. Nally LJ, Wilson DM. Case 6 KCNJ11 R201C – Neonatal Diabetes. Atypical Diabetes. 2018

BOOK REVIEWS

1. **Wilson DM:** Book review. Diabetes, : Nestle Nutrition Workshop Series, Vol 35 Cowett RM [ed], Raven NY, 1995 in Amer J Clinic Nutri 63:789 1996
2. **Wilson DM:** Book review JAMA, Preventing Childhood Obesity: Health in the Balance, JAMA, 295:941, 2006

LETTERS

1. DirecNet (**Wilson DM**): The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes. Diabetes Care 30:185, 2007

OTHER INVITED PUBLICATIONS

1. **Wilson DM:** Therapeutic goals in children with diabetes. Diabetes Dialogue, Diabetes Society of Santa Clara Valley, April 1987
2. **Wilson DM,** Rosenfeld RG: Abnormal growth patterns in children. Child Care Center, pp 43-44, March 1988